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ABSTRACT 
 
INTRODUCTION: Autologous conditioned serum (ACS) is used for treatment of 
osteoarthritis in horses. However, there is a lack of critical knowledge of the contents of 
ACS and any biological effects after injection into osteoarthritic joints. 
 
OBJECTIVE:  The specific aims of this study were to (1) evaluate content of cytokine, 
matrix metalloproteinases (MMP), and tissue inhibitors of matrix metalloproteinases 
(TIMP) in ACS, (2) validate/refute that ACS increases anti-inflammatory or pro-
inflammatory biomarkers in synovial fluid from naturally occurring osteoarthritic joints, 
(3) demonstrate whether freeze/thaw effects IL-1ra concentrations in ACS, and (4) 
evaluate for clinical improvement in lameness following ACS therapy. 
 
METHODS:  Eleven horses with naturally occurring osteoarthritis in a forelimb distal 
inter-phalangeal joint were given 3 consecutive intra-articular doses of ACS separated by 
7-day intervals. Synovial fluid was collected before administration of each dose at day 0, 
7, 14, and 21. Concentrations of cytokines (IL-1ra, IL-1β, TNFα, IL-4, IL-6, IL-8, IL-10), 
MMPs (-1, -3, -9, -13), and TIMPs (-1, -2, -3, -4) were quantified using ELISA and 
multiplex assays. Serum was compared to unincubated and incubated controls and 
synovial fluid was compared to baseline (day 0). Horses were videotaped trotting (at day 
0, 7, 14, and 21) and graded blindly for degree of lameness. 
 
RESULTS: Concentrations of IL-1ra, as well as MMP-1 to TIMP (-1, -2, -3, -4) and 
MMP-9 to TIMP (-1, -2, -4) ratios were increased in ACS (vs. unincubated control), and 
IL-4, IL-6, and IL-8 were decreased in ACS (vs. incubated control). Freeze/thaw did not 
affect biomarker concentrations in ACS. Although ACS contained high concentrations of 
IL-1ra, no changes in IL-1ra concentrations were observed in synovial fluid 7 days after 
each injection. No change in median lameness grade was noted throughout study duration 
(median grade of 1/5 at all time points). 
 
 
 
 
 iv 
 
 
 
Table of Contents 
 
Acknowledgements…………………………………………………………………...…...i 
Dedication……………………………………………………………………………...…ii 
Abstract…………………………………………………………………………………..iii 
Table of Contents…………………………………………………………………….......iv 
List of Tables……….........................................................................................................vii 
List of Figures……………………………………………………………………...…......xi 
 
1. PRELIMINARY LITERATURE REVIEW: 
 
a)  STRUCTURE, FUNCTION, AND HOMEOSTASIS OF A NORMAL 
 EQUINE JOINT.……………………………………………………..…...1 
 
b)  PATHOPHYSIOLOGY OF OSTEOARTHRITIS…………………….…3 
 
c)  CYTOKINES……………………………………………………………11 
 
d)  MATRIX METALLOPROTEINASES AND TISSUE INHIBITORS OF 
 METALLOPROTEINASES…………………………………………….17 
 
e)  AUTOLOGOUS CONDITIONED SERUM……………………………24 
 
 
 
2. HYPOTHESIS, SPECIFIC AIMS, AND RATIONALE:  
 
a)  HYPOTHESIS……………………………………………………...……38 
 
 
 
 
 v 
 
 
 
b)  SPECIFIC AIMS……………………………………………………...…39 
c)  RATIONALE……………………………………………………….…...40 
 
 
3. MATERIAL AND METHODS: 
 
a)   POWER CALCULATIONS………………………………………..……41 
 
b)  STUDY DESIGN…………………………………………………..……42 
 
c)  ELISA AND MULTIPLEX METHODOLOGY.……………….…..…..45 
 
d)  STATISTICAL ANALYSIS……...…………………………….…….…49 
 
 
 
4. RESULTS: 
 
a)  POPULATION AND INCLUSION………………………………..……50 
  
b)  SERUM………………………………………………………...……..…50 
 
c)  SYNOVIAL FLUID……………………………………………………..57 
 
d)  LAMENESS……………………………………………………………..61 
 
e)  CORRELATIONS……………………………………………………….61 
 
 
 
5. DISCUSSION:  
 
a)   SERUM…………………………………………………………………..63 
 
b)  SYNOVIAL FLUID……………………………………………………..66 
 
 
 
 
 
 vi 
 
 
 
c)   LAMENESS……………………………………………………………..68 
 
d)  STUDY LIMITATIONS………………………………………………...68 
 
e)  CONCLUSION………………………………………………………….70 
 
 
6. FUTURE DIRECTIONS………………………………………………………...71 
 
7.  FOOTNOTES……………………………………………………………………74  
 
8. REFERENCES…………………………….………...…………………………..75  
 
 
 
 
 vii 
 
 
 
List of Tables  
 
TABLE 1.1 - Categorization of cytokines based on functional effect on cartilage. 
...............(PAGE 12) 
 
TABLE 1.2 - Categorization of the common families of matrix metalloproteinases 
(MMPs) in joint disease. ...............(PAGE 19) 
 
TABLE 1.3 – ACS treatment protocol developed by Thomas Weinberger for use of 
IRAP for treatment of joint disease in horses (Adapted from Weinberger 2008).  
...............(PAGE 30) 
 
TABLE 3.1 - Pilot multiplex assay data for cytokines and growth factors using 
commercially available human kits (R&D Systemsg). Mean (±SD) concentrations from 
synovial fluid (carpi) and serum from normal (Norm) horses and those with naturally 
occurring OA associated with osteochondral injury (OA). Note: Pilot assays used 
polystyrene beads, whereas magnetic beads were used for the subsequent ACS 
investigation. Significant differences and trends are bolded. * P<0.05, † P<0.3. 
...............(PAGE 41) 
 
TABLE 3.2 - Pilot multiplex assay data for MMPs and tissue inhibitors of 
metalloproteinases (TIMPs) using commercially available human kits (R&D Systemsg). 
Mean (±SD) concentrations from synovial fluid (carpi) and serum from normal (Norm) 
horses and those with naturally-occurring OA associated with osteochondral injury (OA). 
Note: Pilot assays used polystyrene beads, whereas magnetic beads were used for the 
 
 
 
 
 viii 
 
 
 
subsequent ACS investigation. Significant differences and trends are bolded. * P<0.05, † 
P<0.3 ..............(PAGE 42) 
 
TABLE 3.3 – Radiographic grading scale for distal interphalangeal osteoarthritis. The 
average measure intraclass correlation coefficient for agreement of the observers’ distal 
interphalangeal joint radiographic scores in this study was 0.89 (≥ 0.80 is considered 
acceptable). ...............(PAGE 43) 
 
TABLE 3.4 – Radiographic grading scale for navicular bone pathology. The average 
measure intraclass correlation coefficient for agreement of the observers’ navicular bone 
radiographic scores was 0.95 (≥ 0.80 is considered acceptable). ...............(PAGE 43) 
	  
TABLE 3.5 - Homology of equine cytokine, MMP, and TIMP protein sequences 
compared to human, mouse, and rat (determined using NCBI BLASTp software). Note 
that equine and human sequences have the highest percent homology overall (>60% 
homology required for potential cross-reactivity with cytokines [Scheerlinck 1999]), 
making human commercial kits the best option for identifying cytokines in equine fluids. 
Please note that homology alone does not indicate whether equine proteins will interact 
with human-based assays, but provided the starting point as to which species to use.  Pilot 
data with pooled serum and synovial fluid from horses was performed by the 
investigators (unpublished data) to partially validate use of human assays with equine 
matrices (precision, linearity of dilution, parallelism, percent recovery, and stability). 
Note that MMP-2 did not reliably react with either equine fluid and as such was not 
examined in this study. ...............(PAGE 47) 
 
 
 
 
 
 ix 
 
 
 
TABLE 3.6 - Description of the number of samples that were measured below the lower 
limit of quantification for all analytes in serum and synovial fluid. (1 HOUR = 
unincubated serum control; 19 HOUR = incubated serum control; ACS = autologous 
conditioned serum; D0 SF = Day 0 synovial fluid sample; D7 SF = Day 7 synovial fluid 
sample; D14 SF = Day 14 synovial fluid sample; DAY 21 SF = Day 21 synovial fluid 
sample). ...............(PAGE 48) 
 
TABLE 4.1 – Representation of the mean arthrocentesis attempts for arthrocentesis and 
the presence of blood contamination within synovial fluid samples on days 0, 7, 14, and 
21. ...............(PAGE 51) 
 
TABLE 4.2 – Representation of the degree of effusion, subjectively graded as absent, 
mild, moderate, or severe within DIP joints on days 0, 7, 14, and 21. ...............(PAGE 51) 
 
TABLE 4.3 - Overview of cytokine, matrix metalloproteinase, and tissue inhibitors of 
matrix metalloproteinase profile within autologous conditioned serum. Number of values 
below LLOQ (LLOQ = lower limit of quantification) outlines number of analytes that 
measured below lowest standard curve point. For these values, half of the lower limit of 
detection [lowest value statistically different from a blank at 99% confidence] for each 
individual analyte was used as the concentration. ...............(PAGE 53) 
 
TABLE 4.4 - Higher median concentrations (pg/ml) of MMP -1, -9, and -13 and TIMP -
1, -2, -3, and -4 were measured for horses where IL-1ra concentration consistently 
increased (n=2) compared to horses where the IL-1ra concentration consistently 
decreased (n=5), when averaged across study duration.  ...............(PAGE 60) 
 
 
 
 
 
 x 
 
 
 
TABLE 4.5 – Significant (P<0.05) correlations between IL-1ra and various biomarkers 
in ACS and synovial fluid from all sampling time points, determined using Spearman 
rank correlation. ...............(PAGE 62) 
  
 
 
 
 
 xi 
 
 
 
List of Figures 
 
FIGURE 4.1 - Median serum concentrations (with interquartile range) of cytokines IL-
1ra, IL-1β, IL-1ra to IL-1β ratio, TNFα, IL-4, IL-6, IL-8, IL-10. Groups included 1-hour 
unconditioned, unincubated control serum (1HR), 19-hour unconditioned, incubated 
control serum (19HR), fresh autologous conditioned serum (ACS), day 7 freeze-thaw 
ACS (7FT) and day 14 freeze-thaw ACS (14FT). Parametric analyses were performed on 
IL-1ra and IL-8, whereas non-parametric analyses were performed on IL-1β, IL-1ra:IL-
1β ratio, IL-4, IL-6, IL-10, and TNFα. Different letters indicate significant differences 
between groups (P<0.05). ...............(PAGE 54) 
 
FIGURE 4.2 - Median serum concentrations (with interquartile range) of matrix 
metalloproteinases (MMP) -1, -3, -9, and -13, and tissue inhibitors of matrix 
metalloproteinases (TIMP) -1, -2, -3, and -4. See Figure 4.2 legend for group definitions. 
Parametric analyses were performed on MMP-1, MMP-9, TIMP-1, TIMP-2, TIMP-3, 
and TIMP-4, whereas non-parametric analyses were performed on MMP-3 and MMP-13. 
Different letters indicate significant differences between groups (P<0.05). Note: all 
values for MMP-13 represent 50% of the lower limit of detection. ...............(PAGE 55) 
 
FIGURE 4.3 - Median serum MMP to TIMP ratios in 1-hour unconditioned, unincubated 
control serum (1 HR), 19-hour unconditioned, incubated control serum (19 HR), and 
autologous conditioned serum (ACS) groups. Asterisks denote significant difference 
between 1 HR, 19 HR or ACS groups. Significance was set at P<0.05. Parametric ratios 
include MMP1:TIMP1, MMP1:TIMP3, MMP1:TIMP4, MMP3:TIMP3, MMP9:TIMP1, 
MMP9:TIMP3, MMP9:TIMP4, MMP13:TIMP3, and MMP13:TIMP4. Non-parametric 
 
 
 
 
 xii 
 
 
 
ratios include MMP1:TIMP2, MMP3:TIMP1, MMP3:TIMP2, MMP3:TIMP4, 
MMP9:TIMP2, MMP13:TIMP1, and MMP13:TIMP2. ...............(PAGE 56) 
 
FIGURE 4.4 – Median concentrations (with interquartile range) of IL-1ra from 
autologous conditioned serum (ACS-black bars) administered intra-articularly (IA) 
compared to subsequent synovial fluid (SF-grey bars) samples collected after 7-day 
intervals. [1HR Serum=Serum IL-1ra concentration prior to conditioning (control); D0 
SF=Synovial fluid IL-1ra concentration in OA joints at baseline; D0 ACS=ACS IL-1ra 
concentration on day 0; D7 SF=SF IL-1ra concentration 7 days after IA administration of 
D0 ACS; D7 ACS=ACS IL-1ra concentration after freeze/thaw on Day 7; D14 SF=SF 
IL-1ra concentration 7 days after IA administration of D7 ACS; D14 ACS=ACS IL-1ra 
concentration after freeze/thaw on Day 14; D21 SF=SF IL-1ra concentration 7 days after 
IA administration of D14 ACS]. ...............(PAGE 58) 
 
FIGURE 4.5 – Median concentrations (with interquartile range) of analytes in synovial 
fluid, following further grouping of horses based on whether IL-1ra consistently 
increased or decreased compared to baseline. Note: These changes were not analyzed 
statistically due to the small numbers per group. (A) Left Column:  In horses (n = 5) 
where concentration of IL-1ra consistently decreased on day 7, 14, 21 (compared to day 
0), there were also concurrent decreases in IL-8, IL-10, and TIMP-3. (B) Right Column:  
In horses (n = 2) where concentration of IL-1ra consistently increased on day 7, 14, 21 
(compared to day 0), there were also concurrent increases in IL-1β, TNFα (day 7, 14 
only), and MMP-9................(PAGE 59) 
 
 
 
 1 
 
CHAPTER 1: 
PRELIMINARY LITERATURE REVIEW 
 
 
PART A -  STRUCTURE, FUNCTION, AND HOMEOSTASIS OF A NORMAL  
  EQUINE JOINT 
	  
	   Synovial joints are present throughout the mammalian body, and act as an organ 
that facilitates pain-free movement of the limb. Joints are composed of a variety of 
tissues (including articular cartilage, bone, synovial membrane, joint capsule, synovial 
fluid, and ligaments) that work together to provide a functional articulation over the ends 
of two or more bones. Articular cartilage covers the subchondral bone and is surrounded 
by synovial fluid that is produced in the synovial membrane.  Synovial fluid facilitates 
ease of movement, while also acting as a nutritional reservoir for cartilage. Depending on 
the joint, extra-capsular, and/or intra-capsular ligaments are present to provide further 
support (Frisbie 2012a). 
	  
 The synovial membrane is composed of two main tissue layers, called the intimal 
and subintimal layers. The intimal layer interacts directly with the joint cavity, and lines 
the underlying subintimal layer. Unique to the intimal layer are the lack of basement 
membranes and tight junctions. This allows synovial fluid, which originates as an 
ultrafiltrate of plasma from capillaries within the subintimal layer, to secrete into the joint 
cavity. The intimal layer itself can be further subdivided into two main categories of 
cells: type A (macrophage-like) synoviocytes and type B (fibroblast-like) synoviocytes. 
The type A synoviocytes mainly engage in phagocytosis, a function that helps remove 
foreign material from the joint and contributes to the natural turnover of synovial fluid. 
Alternatively, type B synoviocytes predominately act to secrete proteins that are 
important constituents for normal synovial fluid and cartilage health. Such proteins 
include: hyaluronic acid, lubricin, fibronectin, laminin, and proteoglycans (amongst 
others). Cytokines and matrix metalloproteinases (MMPs) from synoviocytes also play an 
important role in influencing anabolic and catabolic processes within the joint (Todhunter 
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1996, Frisbie 2012a). The subintimal layer merges with the true joint capsule, 
contributing to synovial membrane structural support. Together, the intimal and 
subintimal layers become arranged grossly as synovial villi, which act to increase the 
effective surface area of synoviocytes within the joint.  
 
 Articular (hyaline) cartilage is a specialized tissue that contributes to smooth 
movement during flexion and extension of the joint. Articular cartilage is composed of a 
low population of cells (chondrocytes), which produce the more prevalent surrounding 
extracellular matrix. Extracellular matrix is composed predominately of water, collagen, 
and proteoglycan, and to a lesser extent, glycoproteins and minerals. In hyaline cartilage, 
collagen is predominately composed of the type II subtype which acts to provide a 
scaffold for the extracellular matrix and helps withstand tensile forces. Proteoglycans are 
composed of a protein core with glycosaminoglycan side chains. Aggrecan is the most 
common proteoglycan, and is predominately responsible for withstanding compressive 
forces due to the capability of the glycosaminoglycan side chains to attract and retain 
water. Articular cartilage is a unique tissue, in that it lacks vasculature, lymphatics, and 
nerves. Therefore, nutrition for cartilage heath is resultant from diffusion from synovial 
fluid (Todhunter 1996, Frisbie 2012a). 
	  
 Within the normal joint environment, a highly regulated balance exists between 
the synthesis (anabolism) and degradation (catabolism) of the extracellular matrix in 
articular cartilage. This balance allows for the natural turnover and repair of injured 
tissue, which maintains the health of the joint in response to the distribution of forces 
constantly applied through the limb (Mueller 2011). To an extent, cyclical and dynamic 
compression of cartilage stimulates an increase in extracellular matrix deposition (Guilak 
2004). Conversely, static compression or excessive dynamic compression will deplete the 
extracellular matrix and hinder further synthesis (Guilak 2004). This normal balance of 
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synthesis and degradation is constantly ongoing, helping to maintain the health and 
function of a joint. 
 
 
PART B -  PATHOPHYSIOLOGY OF OSTEOARTHRITIS 
 
 Osteoarthritis (OA) is a complex, irreversible disease that affects both animals 
and humans. In humans, OA has been described as the most frequent cause of pain and 
discomfort, with widespread implications for economic loss in the workplace due to 
disability and loss of function (Goldring 2007). Post trauma, the risk of developing 
secondary osteoarthritis ranges from 20 to 50% (Weigel 2002, Dirschl 2004). With age 
(over 65), the majority of human patients develop osteoarthritis in a wide variety of 
joints, and overall, over 27 million adults suffer from clinical OA (Goldring 2007, 
Lawerence 2008). Similar limitations are seen in the equine athlete. Todhunter et. al. 
reported that joint disease was the underlying cause of lameness in 28 to 42% of cases 
(Todhunter 1990). In 1998, horse owners, veterinarians, and trainers were surveyed 
regarding equine health. This study noted lameness (of which osteoarthritis is a major 
contributor) as the most important concern (78% response) (Kane 2000). When 
evaluating annual incidence, cost, and days of lost use, lameness again was found to be 
the main health limitation in the equine industry (Kane 2000). The total cost was 
estimated at $678 million to $1 billion (Kane 2000).  
	  
 Globally, OA is defined as deterioration of articular cartilage, with concurrent 
damage to the synovium and bone. By definition, the Orthopedic Research Society 
International (OARSI) currently defines OA as “a disorder involving movable joints 
characterized by cell stress and extracellular matrix degradation initiated by micro- and 
macro-injury that activates maladaptive repair responses including pro-inflammatory 
pathways of innate immunity. The disease manifests first as a molecular derangement 
(abnormal joint tissue metabolism) followed by anatomic, and/or physiologic 
 
 
 4 
 
derangements (characterized by cartilage degradation, bone remodeling, osteophyte 
formation, joint inflammation and loss of normal joint function) that can culminate in 
illness” (Kraus 2015). 
 
 The word osteoarthritis can be considered a misnomer, as it does not represent a 
traditional inflammatory process due to the lack of neutrophils and cardinal signs of 
inflammation (heat, pain, hyperemia, swelling and loss of function) (Goldring 2007). The 
pathophysiology of OA degeneration follows a similar progression, regardless of the 
initiating cause. Injury to the cartilage can occur from direct trauma or from chronic, 
repetitive stress. Direct damage can cause chondrocyte cell death and structural damage 
to the extracellular matrix. Alternatively, indirect cytokine and chemokine activity can 
increase the concentration of proteolytic enzymes produced by synoviocytes and 
chondrocytes (specifically, MMPs and aggrecanases) within the joint. Central to 
mediating this inflammation are the pro-inflammatory cytokines IL-1 and TNF-α, as well 
as chemokines, prostaglandins and nitric oxide (Goldring 2007). Aggrecanase and MMPs 
are enzymes that degrade the extracellular matrix of cartilage (ie, proteoglycan and type 
II collagen). Normally, these enzymes help maintain normal homeostasis. During 
osteoarthritis, however, abnormal production and activation of proteolytic enzymes result 
in loss of cartilage structure and function. With partial-thickness defects in the superficial 
zone of cartilage, some repair occurs from increased type II collagen and 
glycosaminoglycan synthesis. In mature defects, a healing response with normal hyaline 
cartilage is difficult to attain (Goldring 2007). This is partially due to the low metabolic 
activity for chondrocytes present in the intermediate or deep zones (Goldring 2007). 
Instead, full thickness defects preferentially repair by in-growth of subchondral fibrous 
tissue (composed of type I collagen), which then mature into a fibrocartilage patch 
(Goldring 2007). 
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 Primary synovitis can also lead to secondary changes in articular cartilage, and 
may actually be an early mediator of OA (Benito 2005). McIlwraith, et. al. demonstrated 
this potential in the horse, using intra-articular injection of filipin (a polyene antibiotic, 
produced by Streptomyces organisms) in the intercarpal joint (McIlwraith 1981). 
Following a 12-week course of filipin injections, the histopathological appearance and 
loss of glycosaminoglycan content was similar to that in naturally occurring OA cases. 
Based on these results, it was proposed that primary synovitis may be capable of 
producing pro-inflammatory cytokines that up-regulate catabolic enzymes within the 
joint environment, leading to secondary degeneration of articular cartilage (McIlwraith 
1981).  
 
 The subchondral bone also contributes to OA development and progression. In 
progressively deteriorated joints, common pathological features include increased bone 
deposition (osteophyte formation), increased subchondral bone thickness, and with 
chronicity, development of osseous bone cysts (Buckland-Wright 2004). An increase in 
subchondral bone thickness has been observed in the tarsus of horses with increasing age, 
leading to the proposition that subchondral bone thickening precedes OA formation 
(Murray 2009).  
	  
 OA is a multifactorial disease that can cause variable amounts of damage to the 
joint. One major determinant for degree of injury is the underlying cause. Acute trauma 
causes joint instability through damage to various soft tissue structures (ie, ligaments, 
joint capsule, menisci, or peri-articular soft tissue) (Frisbie 2012a). Alternatively, 
fracture(s) of the osteochondral surface can displace and heal with a maligned joint 
surface. This leads to irregular cartilage surface congruency and chronic secondary 
release of inflammatory mediators (Frisbie 2012a). Developmentally, failure of normal 
endochondral ossification (ie, abnormal cartilage and subchondral bone) can lead to an 
irregular joint surface, detachment of cartilage and subchondral bone, and in select cases, 
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involution and subchondral cyst formation (van Weeren 2012). Depending on the 
anatomical location, normal forces applied to osteochondrosis lesions may result in OA 
(van Weeren 2012). The diseased cartilage and subchondral bone can also up-regulate 
anabolic, anti-catabolic and catabolic cytokines, as well as produce and activate MMPs, 
affecting the entire joint (Trumble 2001). Together, both the irregular cartilage surface 
and secretion of degradative proteins will sustain inflammation within the joint. Lastly, 
and most commonly in the horse, chronic and cyclical absorption of forces distributed 
through the appendicular skeleton can lead to both inflammation of the synovium 
(synovitis) and degeneration of the weight-bearing surface (breakdown of cartilage and 
remodeling of subchondral bone) such that OA is established (Frisbie 2012a). 
 
 Pain, manifested as lameness, is a common clinical presentation of OA. 
Inflammatory debris, resultant from OA, increases effusion (total synovial fluid volume) 
within the joint environment. This leads to overall distension and pressure exerted on the 
joint capsule, where many afferent nociception fibers are present (Frisbie 2012a). During 
the inflammatory cascade, proteins involved in pain transmission (such as substance P) 
are also released (Platt 1996).  Distortion of normal joint anatomy (ie, irregular cartilage 
surface, joint capsule fibrosis, and new peri-articular bone formation) can also create a 
functional impairment of locomotion by decreasing the range of motion (Frisbie 2012a). 
During the early stages of OA, horses can compensate for low-grade pain and mild loss 
of function (Frisbie 2012a). However, if unmanaged, both effusion and lameness 
symptoms progressively worsen. In horses, this is paralleled by a notable decrease in the 
athletic performance (Frisbie 2012a). It is at this point that many owners seek veterinary 
intervention for localization of the lameness and prescription of disease- and symptom- 
modifying therapeutics. 
 
 OA in the horse must always remain a differential diagnosis whenever poor 
performance and/or lameness are localized to a joint(s). Clinical signs of joint injury 
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include decreased range of motion, increased synovial effusion, palpable fibrosis of the 
joint capsule, or enlargement of the adjacent peri-articular bone (Frisbie 2012a). Inducing 
stress by flexing the affected joint can help localize pain by a worsening of the lameness 
(“flexion test”). Once a joint(s) is isolated as symptomatic, radiographic assessment 
commonly follows. It is important to note that radiographs are best for visualization of 
mineralized tissue, with poor visualization of soft tissue structures. As such, cartilage 
defects are not apparent. However, secondary changes in the subchondral bone can be 
seen, such as osteophyte formation, increased bone density (“sclerosis”), decrease(s) in 
joint space, and/or osseous cystic lesions (McIlwraith 2012). With the lack of 
visualization of the cartilage and soft tissue structures, earlier cases of OA are difficult to 
identify. In other words, the lack of radiographic signs of OA does not preclude its 
existence. In fact, the development of radiographic abnormalities in the distal 
interphalangeal joint of the horse is often considered delayed during the early stages of 
OA (Butler 2008). In humans, early cartilage defects can be visualized using magnetic 
resonance imaging (MRI) (Goldring 2007). However, due to limitations in the size of 
horses, technical difficulties, and increased cost of diagnosis, the use of any novel 
imaging (ie, MRI or computed tomography) is less commonly applied.  
 
 Other methods of identifying OA during the early stages of disease progression 
thus remain valuable for diagnosis. With arthroscopy, cartilage lesions can be visualized, 
as well as any pathology of the synovium or internal soft tissue structures (ie, menisci, 
cruciate ligaments) (McIlwraith 2005). Common characteristics of cartilage lesions 
include partial or complete erosion, fibrillation, and/or wear lines (McIlwraith 2005). In 
fact, arthroscopy remains more sensitive than magnetic resonance imaging for detection 
of articular defects, and is considered the ‘gold standard’ ante mortem diagnostic test 
(VanBeek, 2014). Depending on the amount and extent of injuries visualized, prognosis 
for the joint can be inferred during arthroscopy and therapeutic debridement of abnormal 
cartilage can be attempted (McIlwraith 2005, Cohen 2009). Historically, the most 
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important limitation of diagnostic arthroscopy was the necessity of general anesthesia, 
with the risks of traumatic recovery. However, standing arthroscopic techniques have 
been developed for various equine joints. These techniques have the distinct advantage of 
avoiding the inherent risks of anesthetizing horses (Elce 2002, Gasiorowski 2014, Frisbie 
2014).   
 
 Alternate to imaging, measurement of various molecules in body fluids (such as 
synovial fluid) is an active area of research as a means for identifying OA. The molecules 
assessed in samples are generally called ‘biomarkers’, and can either measure molecules 
that directly result from extracellular matrix synthesis/degradation, or those that 
indirectly play a role in OA pathogenesis such as cytokines, growth factors, MMPs and 
tissue inhibitors of matrix metalloproteinases (TIMPs). Historically, cytokines have been 
measured in equine synovial fluid by using enzyme linked immunoabsorbance assay 
(ELISA) or reverse transcriptase polymerase chain reaction (rtPCR) to detect mRNA 
expression (Trumble 2001, Kamm 2010). Alternatively, gelatin zymography has been 
used to quantify MMP concentrations (Clegg 1997, Trumble 2001) and reverse 
zymography for TIMP concentrations (Clegg 1998). More recently multiplex assay has 
been used to quantify multiple indirect biomarkers simultaneously from the same serum 
or synovial fluid sample. Multiplex assays utilize a bead based, flow cytometer system 
that can evaluate up to 100 different analytes. Each bead is internally color-coded with 
varying ratios of 2 fluorescent dyes. This allows an analyte of interest to be measured 
through covalent coupling to specific capture antibodies. One laser identifies the specific 
bead set, and another laser quantifies the florescent reaction to the antibody. Then, the 
florescent reaction can be compared against a standard curve (similar to an ELISA), to 
also provide quantitative results. The obvious advantage of this technology compared to 
the previously mentioned techniques is the relative efficiency in measuring multiple 
analytes from small fluid volumes. Additionally, it has been suggested that the multiplex 
technology may be more sensitive than traditional ELISAs (van Gageldonk 2008). Using 
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multiplex technology for investigating OA has been successfully performed in human 
medicine, and has similar potential for equine research (Cattano 2011, Beekhuizen 2013, 
Heard 2013, Tsuchida 2014, Monibi 2015).  
 
 As previously mentioned, OA is an irreversible disease. As such, management 
strategies for therapy are ultimately aimed at minimizing the inflammatory and 
degradative damage of OA, thereby decreasing pain and minimizing ongoing damage. 
Surgically, this can be accomplished via removal of incongruent osteochondral fragments 
and/or abnormal cartilage, such that fibrocartilage ingrowth can occur. Therapeutics are 
directed towards providing a net anti-inflammatory change. Common medications 
include systemic non-steroidal anti-inflammatories (ie, phenylbutazone, firocoxib) and 
joint supplements (ie, glucosamine, chondroitin sulfate); and/or intra-articular 
corticosteroids (ie, methylprednisolone, triamcinolone) and hyaluronic acid (Frisbie 
2012b). Novel biological therapies, such as autologous conditioned serum, platelet-rich 
plasma, or stem cells have also become popular recently (Frisbie 2007, Textor 2011, 
Brehm 2014).  
 
 In the equine athlete, OA can occur in any joint. Depending on the type of sport a 
horse participates in, certain joints develop OA more often. Commonly, the metacarpal 
(tarsal)-phalangeal, radiocarpal, and middle carpal joints are affected in Thoroughbred 
racehorses (Frisbie 2012b). In fact, 33% of all 2- and 3- year old racing Thoroughbreds 
had cartilage lesions and pathological signs of osteoarthritis in the metacarpophalangeal 
joint in a retrospective study of 50 racehorses (Neundorf 2010). Alternatively, in Western 
and English performance horses, injury to the femorotibial, distal intertarsal, and 
tarsometatarsal joints is more prevalent (Ferris 2011). The distal interphalangeal joint 
(DIP) was commonly affected in dressage and hunter/jumpers in another retrospective 
study (Kristiansen 2007). Interestingly, the presence of DIP joint effusion alone does not 
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always correlate with clinical signs of lameness. Thus, physical exam alone can make the 
diagnosis of DIP joint OA difficult and potentially over-represented (Olive 2014). 
 
 In horses, the incidence of OA increases with age. As OA is a degenerative 
process, manifestations of OA worsen over time. However, there are other structural 
changes known to develop within the joint as the result of age, and not exclusively 
attributable to OA. In humans, increasing stiffness and decreasing tensile strength of 
extracellular matrix occurs because of changes in type II collagen and proteoglycan 
(Aigner 2007). This is thought to result from decreased anabolic capabilities of cells 
(Aigner 2007). Limited specific studies of microscopic structural changes in cartilage 
with respect to horse age have revealed elevated concentrations of prostaglandin-E2 in 
cartilage samples of older horses (>20 years) compared to young (<10 years) following 
exposure to lipopolysaccharide (Briston 2010). In another study, cartilage in 
tarsometatarsal joints showed decreasing hyaline cartilage and increasing calcified 
cartilage quantity with age (Murray 2009). With this knowledge, one can hypothesize that 
as horses become older, articular cartilage may become less able to withstand normal 
cyclical forces, increasing the risk of OA. 
 
 In general, OA is a complex disease resulting in significant debility for the equine 
patient and notable economic strains in the horse industry. Osteoarthritis can develop 
from a wide variety of inciting causes. Cartilage, synovium, and subchondral bone all 
play a role in OA pathophysiology. Proper management of OA is highly dependent on 
early detection. However, no ideal diagnostic tool yet exists. Depending on the severity 
of OA, a variety of therapeutics exists, but none can cure established OA. Furthermore, 
the study of OA in horses not only will benefit that species, but also provides a good 
translational model for human OA. 
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PART C -  CYTOKINES 
 
 Cytokines are a diverse group of immunological proteins that are ubiquitous in all 
organs and tissues. Cytokines play a key role in synovitis and osteoarthritic disease 
(Goldring 2004). Cytokines have an important role in cell signaling and influence the 
inflammatory environment either positively or negatively. This is accomplished 
predominately by autocrine (internal signaling within the same cell) or paracrine 
(external signaling between two cells within the same organ) function (Goldring 2004). A 
third, unique mechanism exists where cytokines remain associated with the surface of 
their origin cell, but interact with receptors on other cells (juxtacrine signaling) (Goldring 
2004). Cytokines can be either a part of the cell surface or soluble within the joint fluid, 
and are produced by both chondrocytes and synoviocytes (Goldring 2004). During 
osteoarthritic progression, it has been proposed that cytokines increase in concentration 
and diffuse through synovial fluid, thereby influencing articular cartilage locally (Martel-
Pelletier 1999). 
  
 Within the joint environment, cytokines influence the progression of osteoarthritis 
through a variety of mechanisms, which can be subdivided into four broad categories 
(Goldring 2004). Cytokines can bind to a target receptor, which subsequently up-regulate 
other proteolytic factors within the joint (catabolism). Opposing this, certain cytokines 
act to directly or indirectly antagonize the catabolic cytokines (anti-catabolism). Other 
cytokines can directly signal and influence the synthesis of chondrocytes and 
synoviocytes (anabolic). Lastly, some cytokines lack an obvious beneficial or detrimental 
effect, yet have the ability to modulate the effects of other cytokines (modulatory). 
Classification of the various types of cytokines present can be broadly simplified into 
separate groups by these outcomes (Table 1.1). 
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Function in Joint Cytokine 
Catabolic IL-1, TNF-α, IL-2, IL-8, IL-17, IL-18, 
Anti-Catabolic IL-1ra, IL-4, IL-10, IL-13 
Anabolic IGF-1, TGF-β, VEGF 
Modulatory IL-6, IL-11 
 
TABLE 1.1 – Categorization of cytokines based on functional effect on cartilage. 
 
 Of the catabolic cytokines, interleukin-1 (IL-1) is central in promoting 
inflammation. Interleukin-1 has two structurally different, but functionally similar 
molecular subtypes, denoted as alpha (α) and beta (β). Previous human studies have 
demonstrated the importance of IL-1 in osteoarthritis pathogenesis (Dodge 1989, Smith 
1989, Lefebvre 1990). The important role of IL-1 has also been demonstrated in equine 
studies (Alwan 1991, Trumble 2001). In vitro, when cartilage is exposed to IL-1, up-
regulation of proteolytic enzymes (including the wide array of MMPs) occurs (McGuire-
Goldring 1984). In vivo, when recombinant IL-1 is injected directly into the joint 
environment, proteoglycan loss occurs (Pettipher 1986). This method has also been used 
as a model of arthritis in horses (Pearson 2009, Ross 2012).  
  
 The source of IL-1 is predominately from synoviocytes or chondrocytes, but can 
also come from inflammatory cells that infiltrate the joint (Goldring 2004). IL-1 
predominately signals through binding of specific IL-1 receptors, which initiates cellular 
signaling and influences gene transcription of other cytokines and proteolytic enzymes 
(Richardson 2000, Sutton 2009). Beyond up-regulation and activation of proteolytic 
enzymes, other notable cellular effects of IL-1 include inhibition of proteoglycan 
synthesis, indirect up-regulation of additional catabolic cytokines (ie, TNFα), release of 
angiogenic factors, chondrocyte apoptosis, inhibition of TIMPs, and nitric oxide release 
(Sutton 2009).  
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 One previous investigation examined IL-1 mRNA expression from chondrocyte 
and synovial membrane tissue in normal, osteochondrosis, and osteoarthritis affected 
horses (Trumble 2001). No significant difference in IL-1α expression was noted between 
normal and osteoarthritic joints. As well, no effect of age was reported (Trumble 2001). 
In contrast, a significant difference in expression of IL-1β was noted between 
osteoarthritic and normal samples of synovial tissue and an age related effect was also 
observed, with younger horses demonstrating increased expression. In articular cartilage, 
IL-1β showed no significant difference between healthy and osteoarthritic joints. 
However, IL-1β expression in articular cartilage was correlated with both the white blood 
cell count and MMP-3 concentrations (Trumble 2001). A correlation also existed 
between IL-1α and IL-1β expression (Trumble 2001). Conversely, in osteoarthritic 
equine radiocarpal joints, IL-1 was found to be highly elevated within articular cartilage, 
but not synovial tissue (Kamm 2010). In another study, IL-1β showed a high variability 
in concentration within normal joints. As such, using measurements of IL-1β 
concentrations yields low specificity for inferring underlying osteoarthritic disease 
(Bertone 2001).  
 
 Another important catabolic cytokine involved in equine osteoarthritis is tumor 
necrosis factor alpha (TNFα). TNFα induces an almost identical list of physiological 
effects within the joint as previously described for IL-1 (Goldring 2004). By comparison, 
IL-1 is 100 to 1000 times more potent than TNFα (van den Berg 2001). There is a strong 
synergistic relationship between IL-1 and TNFα, with each causing up-regulation of 
production of the other (Henderson 1989). In osteoarthritic equine radiocarpal joints, 
TNFα was found to be significantly increased in both synovial and chondrocyte tissue 
(Kamm 2010). In equine chondrocyte tissue, osteoarthritic joints had higher TNFα 
expression compared to normal joints (Trumble 2001). TNFα may be more active during 
the early stages of osteoarthritis (Billinghurst 1995, Trumble 2001). When evaluating 
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concentrations of TNFα in normal and osteoarthritic joints, it was concluded that horses 
with TNFα concentrations in the top 75th quartile were 5.7 times more likely to have 
acute, severe joint disease (Bertone 2001). It was concluded that elevated TNFα (50th 
percentile or higher) is a very good indicator of osteoarthritis, but not progression. 
However, concentrations of TNFα do not appear to correlate well with the degree of joint 
pathology (Ley 2007, Jouglin 2000). TNFα concentrations in osteoarthritic joints do not 
seem to be influenced by a previous history of intra-articular corticosteroid injections 
(Ley 2007). 
 
 The third main catabolic cytokine is IL-8. This protein acts to promote 
inflammation in the joint, predominately through recruitment of neutrophils and 
induction of phagocytosis (David 2007). IL-8 is also referred to as a chemokine due to 
this function (David 2007). Other cellular responses to IL-8 are promotion of 
angiogenesis (Koch 1992) and release of MMPs (Borzi 2000). In an in vitro equine 
chondrocyte culture, IL-8 was significantly up-regulated following exposure to IL-1 
(David 2007). IL-2 also has catabolic function in the joint through effects on T-
lymphocyte recruitment and proliferation (Martel-Pelletier 1999). Relatively little is 
known about IL-2 concentrations in equine arthropathies. 
 
 Anti-catabolic cytokines, as the name implies, act to diminish the effect of 
catabolic proteins (ie, IL-1 and TNFα). One of the most fundamental anti-catabolic 
cytokines is interleukin-1 receptor antagonist protein (IL-1ra) (Goldberg 2004). 
Normally, the relationship between IL-1ra and IL-1/TNFα helps promote chondrocyte 
metabolism and turnover during normal joint homeostasis (Goldberg 2004). IL-1ra 
antagonistically binds to IL-1 receptors on the chondrocyte cell surface (Hannum 1990, 
Goldring 2004) to prevent IL-1 from binding to that site, thereby preventing cellular 
signaling in response to IL-1 (Hannum 1990). If an ample concentration of IL-1ra exists 
in the joint, then IL-1 signal is suppressed, and less MMP up-regulation will occur. This 
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concept was confirmed in horses using gene therapy to up-regulate intrinsic IL-1ra in the 
joint (Frisbie 2002). A significant improvement in osteoarthritis scores was seen when 
higher concentrations of circulating IL-1ra were present (Frisbie 2002).  
 
 The other major anti-catabolic cytokines are IL-4, IL-10, and IL-13. These 3 
cytokines prevent and suppress cartilage degradation in a variety of ways. Interleukin-4, -
10, and -13 can directly suppress proteolytic-induced cartilage degradation (Goldring 
2004). Indirectly, IL-4, -10, and -13 can decrease the production of various pro-
inflammatory cytokines (such as IL-1 and TNFα) from synoviocytes and chondrocytes 
(Alaaeddine 1999). In an in vitro study, IL -4, -10, and -13 have been shown to increase 
the concentration of IL-1ra (Fernandes 2002). IL-4 has been shown to inhibit osteoclasts, 
which are involved in bone remodeling during osteoarthritis. (Shioi 1991).  IL-4 and IL-
13, but not IL-10, have been shown to inhibit synoviocyte apoptosis (Relic 2001) which 
can perpetuate further synovial membrane hyperplasia in chronic, osteoarthritic joints. 
This effect illustrates one potentially negative effect of the aforementioned cytokines. In 
an in vitro study of the effects of IL-1 on various other cytokine families, equine 
chondrocyte cells were exposed to recombinant IL-1 and no up-regulation of IL-4 
occurred; therefore IL-4 activity may not be linked to the catabolic cytokines (David 
2007).  
 
 Anabolic cytokines directly promote synthesis by chondrocytes, synoviocytes, 
and osteoblasts. The two most important cytokines in this family include insulin-like 
growth factor -1 (IGF-1) and transforming growth factor – beta (TGF-β). IGF-1 promotes 
chondrocyte proliferation and synthesis of the extracellular matrix (Maor 1993, 
Davenport-Goodall 2004). When IGF-1 is co-cultured with osteogenic protein, both 
normal and osteoarthritic tissue cultures increased proteoglycan quantity (Loeser 2003). 
Additionally, IGF-1 influences aggrecan, decorin, and type II collagen production 
(Chubinskaya 2007). When equine synoviocytes and chondrocytes are exposed to IGF-1 
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in-vitro, an increase in production of type II collagen and proteoglycan is identified. 
(Haupt 2005). Indirectly, IGF-1 antagonizes IL-1 production, such that less proteolytic 
enzymes are present (Im 2003). Using gene therapy for IGF-1 or IGF-1 combined with 
IL-1ra, an improvement in proteoglycan content and type II collagen was noted in 
cartilage samples (Morisset 2007).  
 
 A second important anabolic cytokine is TGF-β. Similar to IGF-1, TGF-β appears 
to increase proteoglycan concentrations in the joint. Also similar to IGF-1, TGF-β 
appears to reduce production of IL-1β by both decreased expression of IL-1 itself, as well 
as decreased expression of IL-1 receptors (Harvey 1991). Through this path, TGF-β 
indirectly minimizes cartilage degradation (Harvey 1991). Interestingly, for both IGF-1 
and TGF-β, the physiologic changes induced in the joint are not always beneficial. Both 
cytokines may contribute to osteophyte formation during the later stages of osteoarthritis 
(Horner 1998, Okazaki 1999). In one study, TGF-β increased concentrations of MMP-9 
(but not MMP-2) in normal equine chondrocytes (Thompson 2001). Lastly, vascular 
endothelial growth factor (VEGF) is an anabolic cytokine produced by chondrocytes that 
can promote angiogenesis within synovium and other inflamed tissue (Honorati 2004).  
 
 The last group of cytokines is classified as modulatory. Cytokines that are a part 
of this group include IL-6 and IL-11. Modulatory is a term used to describe the ability of 
these cytokines to regulate the inflammatory environment, either in a pro- or anti- 
inflammatory manner, depending on the circumstance. IL-11 has apparently not been 
investigated in horses. IL-6 can induce anti-inflammatory and chondroprotective effects, 
through induction of IL-1ra and TIMPs (Goldring 2004). Indirectly, IL-6 blocks IL-1 
ability to inhibit proteoglycan synthesis. Yet, counter-intuitively, IL-1 stimulates IL-6 
production in the joint (Neitfeld 1994). In some instances, IL-6 directly inhibits 
proteoglycan and chondrocyte synthesis (Goldring 2004). IL-6 also up-regulates MMP 
and aggrecanase activity within the joint (Goldring 2004). In one study, IL-6 was 
 
 
 17 
 
significantly elevated in joints with osteochondral fragment(s) and secondary 
osteoarthritic changes, compared to healthy joints (Ley 2007). In this study, the grade of 
osteoarthritis present correlated with IL-6 concentrations in the synovial fluid (Ley 2007). 
This same study also found that IL-6 was usually higher in those joints that had no 
previous intra-articular corticosteroid injection (Ley 2007). Using joint fluid from normal 
(n=50) and diseased (n=69) horses, elevated concentrations of IL-6 were highly sensitive 
and specific for ruling in/out osteoarthritic disease (Bertone 2001).  
 
 A wide variety of cytokines exist, and within the joint environment, the cellular 
effects from cytokine activity (ie, pro- or anti-inflammatory action) are highly variable. 
Many complex relationships exist between the multitude of cytokines present, with many 
having a positive or negative influence towards each other. Measuring an individual 
cytokine concentration alone does not provide clarity regarding the health of a joint. 
Comparatively, profiling groups of cytokines may provide a better understanding of the 
entire joint environment. Assessment of cytokines from each of the four sub-families 
(catabolic, anti-catabolic, anabolic, modulatory) would be ideal. A cross-sectional 
sampling of cytokines will help understanding of the function and interactions of each 
cytokine, as well as their relationship to the onset and progression of joint disease. 
Secondarily, a more objective assessment of the efficacy of joint therapeutics can be 
attained. 
 
 
PART D –  MATRIX METALLOPROTEINASES AND TISSUE INHIBITORS OF 
METALLOPROTEINASES  
 
 
 Matrix metalloproteinases (MMPs) can be found in a variety of organ systems 
within the body, including the joint. They are zinc dependent enzymes that are active in 
the normal remodeling of articular cartilage. MMPs are secreted as inactive zymogens, 
requiring enzymatic cleavage to become functional (Murphy 1990). In the joint 
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environment, MMPs cause degradation of the extracellular matrix (Clutterbuck 2010). 
For normal growth and regeneration to occur, MMP-induced degradation is an important 
initial step (Clutterbuck 2010). Degradation of the extracellular matrix by MMPs also 
imparts indirect, secondary effects, such as release of various growth factors, such as 
fibroblast growth factor (Whitelock 1996). However, MMP degradation of the 
extracellular matrix is closely controlled by an opposing family of endogenous proteins, 
aptly called tissue inhibitors of MMPs (TIMPs). TIMPs are proteins that directly 
antagonize the effects of MMPs (Clutterbuck 2010). In normal joint physiology, a 
controlled balance exists between the activated MMPs and TIMPs, which allows for the 
continued health of articular cartilage (Clutterbuck 2010).  
 
 If the balance between activated MMPs and TIMPs becomes disrupted, damage to 
the joint can occur. Either an excessive increase in MMP concentrations or decrease in 
TIMP concentrations can contribute to a degradative state (Yoshihara 2000). Joint disease 
is a relevant example of normal and abnormal MMP/TIMP balance in physiology 
(Clutterbuck 2010). Approximately 5% of the total MMP concentration is present in an 
active form within the healthy joint (Murphy 1990). The remaining 95% of inactive 
MMPs are present latently within the joint, or are bound with respective TIMPs (Brama 
2000). The ratio of active to inactive MMPs increases with the establishment of 
osteoarthritis (Murphy 1990). Logically, the higher the concentration of active MMPs 
present, the more degradation that occurs within the joint. The pro-inflammatory cytokine 
IL-1 up-regulates various MMPs (Clutterbuck 2010). Interestingly, MMPs can, in-turn, 
degrade IL-1. This implies that a negative feedback loop exists, further exemplifying the 
close inter-relationship between the many various proteins within the joint (Clutterbuck 
2010). Beyond IL-1, up-regulation of MMPs can occur from inherent extracellular matrix 
components, various growth factors, and certain exogenous pathogens (Khokha 2013). 
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 Aside from the joint, the pathologic effect of excessive MMPs has been widely 
documented in a variety of other clinical diseases in the horse, such as laminitis, hepatitis, 
nephritis, recurrent airway obstruction, colic, epidermal wounds, ocular ulcerative 
keratitis, and neoplasia (Iredale 2006, Arosalo 2007, Clutterbuck 2010). In a study of 
equine osteoarthritis in the metacarpo- (metatarso-) phalangeal joint, general MMP 
activity (as measured by a fluorometric assay technique) was significantly increased (van 
den Boom 2005). This MMP activity was positively correlated with the degree of 
cartilage erosion, as well as the concentration of hydroxyproline, an amino-acid sequence 
in type II collagen, shed during degradation (van den Boom 2005). 
 
 A variety of subtypes exist within the MMP family, and are either classified 
numerically (ie, MMP-1) or based on the enzymatic name, which infers the substrate that 
is most actively degraded by a specific MMP (ie, collagenases breaks down collagen). 
Most MMPs may degrade multiple substrates, but generally prefer the substrate found 
within the enzymatic name (Clutterbuck 2010). An example of this multi-functional 
activity is MMP-1, which is predominately active in degrading collagen, but will also 
degrade glycoprotein, gelatin, and proteoglycan. An overview of the more common and 
active MMPs in joint disease, correlated to their general enzymatic substrate name, is 
provided (Clutterbuck 2010) (Table 1.2). It is important to note that the complete list of 
identified MMPs in mammals is much more comprehensive than those described below. 
 
 
PREDOMINANT SUBSTRATE 
SPECIFICITY 
MATRIX METALLOPROTEINASE 
Collagenases MMP  -1,  -8,  -13,  
Gelatinases MMP  -2,  -9 
Stromelysins MMP  -3,  -10,  
TABLE 1.2 - Categorization of the common families of matrix metalloproteinases 
(MMPs) in joint disease.  
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 Collagenases (MMP-1, -8, -13) have a central role in osteoarthritis, as articular 
cartilage has a high component of type II collagen. Collagenases denature collagen by 
cleaving all 3 alpha chains of the collagen triple helix 3/4 of the length from the amino 
terminus (Billinghurst 1997). They have minor roles in breaking down glycoproteins, 
gelatin, and proteoglycans (Clutterbuck 2010). MMP-13 is more efficient at type II 
collagen degradation than the other collagenases, being 10 times faster than MMP-1 
(Mitchell 1996). In general, MMP-13 is not considered a major contributor to joint 
homeostasis due to the low concentrations present in normal joints when compared to 
diseased joints (Reboul 1996, Trumble 2001). Alternatively, MMP-13 is thought to be 
active in the remodeling process of osteoarthritis, and therefore more likely to be elevated 
in diseased joint environments (Tardif 1999, Trumble 2001). The significance of MMP-1 
in osteoarthritis is conflicting. MMP-1 concentrations were found to be higher than 
MMP-13 in human osteoarthritic joints (Shlopov 1997). mRNA expression of both MMP 
-1 and -13 were elevated in equine chondrocyte cultures that were stimulated with 
recombinant IL-1β (Tung 2002). In synovial tissue samples collected from horses with 
osteoarthritis (n=59), only 5% of cases identified mRNA expression of MMP-1, whereas 
8% of cases identified mRNA expression of MMP-13 (Trumble 2001). No chondrocytes 
expressed MMP-1, whereas 22% of chondrocytes had MMP-13 expression (Trumble 
2001). When evaluating MMP-1 concentrations in fetal, juvenile, and adult horses with 
normal joints, the concentration of MMP-1 progressively declined with age (Brama 
2004). In horses with metacarpophalangeal joint osteoarthritis, concentration of MMP-1 
was significantly elevated compared to normal age-matched horses (Brama 2004).  
 
 The function of the gelatinase family of MMPs (-2 and -9) is to degrade gelatin 
and unwind collagen (Murphy 1990). These MMPs also display activity against 
proteoglycan, collagen, laminin, elastin, and glycoproteins (Clutterbuck 2010). 
Gelatinases play an important role in equine osteoarthritis (Clegg 1999, Jouglin 2000). A 
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2 to 3 fold elevation of MMP-2 concentration has been identified in osteoarthritic joints, 
compared to normal horse joints (Clegg 1997). Increased MMP activity was found in 
metacarpo- (metatarso-) phalangeal osteoarthritis, which was predominately attributed to 
MMP-2 and -9 (van den Boom 2005). Gelatinase activity was noted in 76 joint samples 
from horses with naturally occurring osteoarthritis. The concentration of inactivated 
MMP-2 was elevated in 100% of OA joints. Activated MMP-2, however, was only 
detected in 3% of the study population (Trumble 2001). Inactivated MMP-2 may be an 
important component of normal joint homeostasis, and only becomes activated in 
response to disease (Clegg 1999). Unique to MMP-2, the inactivated form becomes 
activated by exposure to cell surface membranes, which is in contrast to other MMPs that 
require proteolytic enzyme cleavage (Clegg 1999). Elevated MMP-2 concentrations were 
positively correlated with older horses with acute, traumatic osteoarthritis, and negatively 
correlated with older horses with chronic, traumatic osteoarthritis (Trumble 2001).  
 
 Inactivated MMP-9 was found in only 43% of joints, and activated concentrations 
in 17% (Trumble 2001). MMP-9 does not appear to be a major contributor to normal 
joint homeostasis, however does become increasingly active during osteoarthritis 
secondary to joint sepsis (Trumble 2001). MMP-9 is highly abundant in the tertiary 
granules of neutrophils, and is released upon stimulation by IL-8 or TNFα (Khokha 
2013). Interestingly, monitoring the concentration of MMP -2 and -9 allows for the 
prediction of survivability of horses with septic arthritis (Kidd 2007).  
  
 Similar to other MMP families, the production and activation of gelatinases 
during osteoarthritis occurs mainly by exposure to IL-1. This effect was demonstrated 
with MMP-2 using in vitro equine articular chondrocyte and synovial fibroblast cell 
culture (Clegg 1999). In this same study, IL-1 also influenced MMP-9 in synovial tissue, 
however it did not affect MMP-9 in articular cartilage itself (Clegg 1999). In human 
osteoarthritis studies, MMP-9 is also up regulated directly by exposure to MMP-2, and 
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other MMP subtypes, such as MMP -1, -3, -7 (Fridman 1995, Woessner 1991). In horses, 
pro-MMP-2 may increase MMP-9 (Trumble 2001). 
 
 The stromelysin family of MMP enzymes (-3, -10) functions in multiple pathways 
within the joint. Stromelysins contribute primarily to proteoglycan degradation, but also 
effect collagen (IX and XI), laminin, glycoproteins, elastin, and gelatin (Brama 2000, 
Clutterbuck 2010). Stromelysins can also activate MMP-1, -9, and -13 (Brama 2000). Of 
the stromelysins, MMP-3 has been implicated as the most active in osteoarthritis (Brama 
2000). In human osteoarthritic joints, MMP-3 was found at high concentrations in 
synovium and extracellular matrix, whereas MMP-10 was not observed (Hembry 1995). 
In samples from horses with osteoarthritis, 86% of synovial samples (n=59) and 80% of 
chondrocyte (n=45) samples had elevated MMP-3 expression (Trumble 2001). In normal 
metacarpophalangeal and tibiotarsal joints, MMP-3 concentrations were found to be 
significantly elevated during fetal and juvenile growth (Brama 2000). MMP-3 
concentrations decreased as horses aged (Brama 2000). However, osteoarthritic 
metacarpophalangeal joints had MMP-3 concentrations that were 4-fold higher than age 
matched controls (Brama 2000), highlighting the importance of MMP-3 in osteoarthritis. 
Chondrocytes and synoviocytes can up-regulate MMP-3 production in the joint, and this 
up-regulation is initiated mainly by IL-1 (Hasty 1990).  
 
 A variety of factors beyond osteoarthritis influence changes in MMP 
concentrations within the joint. Younger horses have increased joint metabolism, leading 
to increased cartilage turnover. As such, juvenile horses (those less than 4 years old) have 
increased MMP concentrations compared to mature horses in which cartilage metabolism 
slows down (Brama 1998). MMPs play an important role in cartilage development and 
maturation. Arthrocentesis likely incites local inflammation within the synovium, and 
increases MMP concentrations (van den Boom 2004). After 2.5 and 7 days, MMP 
concentrations were abnormally elevated due to arthrocentesis (van den Boom 2004). In 
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another study, MMP-1 concentrations were found to be elevated at 12 hours, but returned 
to baseline by 60 hours (Brama 2004). When correlating different joints and MMP 
concentrations following arthrocentesis, the radiocarpal and metacarpo- (metatarso-) 
phalangeal joints showed higher elevations (relative to baseline) compared to the 
tibiotarsal joint (van den Boom 2004). It was postulated that the larger volume of the 
tibiotarsal joint resulted in more dilution of MMPs, accounting for the difference (van 
den Boom 2004). Moderate exercise did not change MMP concentrations in normal 
metacarpophalangeal joints (van den Boom 2004). However, excessive exercise or joint 
disease may give a different response (van den Boom 2004, Pap 1998, Roos 1995).  
  
 Tissue inhibitors of matrix metalloproteinases (TIMPs) are endogenous proteins 
that oppose MMP function. Four TIMPs are involved in MMP antagonism (TIMP -1, -2, 
-3, and -4). TIMPs bind directly to the active site for MMP proteins and render its 
degradative function inert (Khokha 2013). TIMPs bind only active MMP proteins; they 
exert no interaction with the inactive MMP state (Khokha 2013). Each of the four 
subtypes of TIMPs exert an effect against multiple MMPs (Khokha 2013). In addition to 
the primary role of antagonizing MMPs and aggrecanases, TIMPs contribute to 
extracellular matrix remodeling by influencing cell growth and apoptosis (Chirco 2006). 
IL-1 stimulates production of various MMPs and actively suppresses TIMP production, 
augmenting the pro-inflammatory environment in osteoarthritis (Martel-Pelletier 1994). 
In horses, TIMP-1 and -2 are produced by chondrocytes and fibroblastic synoviocytes, 
with TIMP-1 also from monocytes in blood (Clegg 1998). Further equine-specific studies 
evaluating TIMP-3 and -4 are not available; however, inferring from human literature, 
TIMP-3 and -4 also originate from chondrocytes, synoviocytes and monocytes (Khokha 
2013). 
 
 MMPs and TIMPs are vital participants in the development, maturation, and 
maintenance of the normal equine joint and are also important in synovitis and 
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osteoarthritis. Detrimental effects of MMPs occur through a wide variety of degradative 
functions. To improve understanding of the development and efficacy of various joint 
therapies, it will be important to define the role of MMP and TIMP activity in the joint.  
 
PART E –  AUTOLOGOUS CONDITIONED SERUM 
 
 Autologous conditioned serum (ACS) is a novel therapeutic that has been used in 
human and veterinary medicine for a variety of disorders. The word ‘autologous’ defines 
this therapeutic as being derived from the same individual that would be treated. ACS is 
an acellular composition of multiple blood-derived immunological proteins. Serum is 
specifically altered to up-regulate IL-1ra, which is a pure, specific antagonist to IL-1 
(Meijer 2003). 
	    
 The first report of IL-1ra came from a case series of 3 patients affected with 
monocytic leukemia, in which a protein was present in high concentrations in the 
patients’ urine that inhibited the pro-inflammatory effects of IL-1 (Balavoine 1986). This 
unknown, new protein, which later became classified as IL-1ra, was further explored in a 
cultured fibroblast model and found to reduce up-regulation of prostaglandin E2 and 
collagenase (MMP-1) through antagonism of IL-1 (Balavoine 1986). Due to the 
underlying cancer lineage in these patients, it was postulated that IL-1ra is predominately 
produced by monocytes (Balavoine 1986). Further investigation showed that IL-1ra binds 
to IL-1 receptors present on a variety of cell surfaces throughout the body (Hannum 
1990). Binding affinity of IL-1ra for the IL-1 receptor was found to be nearly equal to 
that of IL-1 (Arend 1990). These receptors, when bound with IL-1ra (instead of IL-1) 
showed no agonist response. As such, IL-1ra was identified as a pure, receptor antagonist 
that facilitates an indirect anti-inflammatory response through the direct blockage of IL-1 
activity (Hannum 1990).  
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 The beneficial effect of the IL-1ra in joints has previously been demonstrated in 
various animal models of OA. In one study, canine stifle joints were medicated with 
human-recombinant IL-1ra, following transection of the cranial cruciate ligament. Dogs 
received 2 or 4 mg of human-recombinant IL-1ra (vs. saline control) intra-articularly 
twice weekly, for 4 weeks duration. This study found that human-recombinant IL-1ra 
exerted a dose dependent effect, noted by a reduced osteophyte size and number, as well 
as decreased size and severity of cartilage lesions (Caron 1996). Additionally, expression 
of mRNA of matrix metalloproteinase-1 (MMP-1) concentrations decreased following 
therapy (Caron 1996). Another study utilized a homologous gene sequence carried by an 
adenoviral vector to induce up-regulation of IL-1ra within the joint. Following induction 
of osteoarthritis using an osteochondral model of OA in the equine carpus, intra-articular 
injections of adenovirus IL-1ra vector were performed (Frisbie 2002). Following IL-1ra 
gene therapy, a subjective improvement in lameness scores, decrease in synovial 
effusion, and decrease in proteoglycan loss (based on Safranin-O and Fast Green 
staining) was identified in treated joints (Frisbie 2002). The intra-articular concentration 
of IL-1ra was also up regulated at day 7, 14, and 21 following introduction of the vector 
(Frisbie 2002).  
  
 With continued research, up-regulation of IL-1ra from the monocyte could be 
externally stimulated by exposure to a variety of factors, such as immunoglobulin G, 
lipopolysaccharide, and most notably, various glass surfaces (Arend 1990, Meijer 2003). 
This allowed for the development of medical devices that could be used bedside 
relatively easily, and has been utilized for an assortment of medical disorders in humans. 
Even though ACS is a generic term, these medical devices have generally been referred 
to as ACS. In humans, ACS has mostly been used to treat osteoarthritis (Yang 2008, 
Baltzer 2009, Baltzer 2013), however it has also been administered with positive 
outcomes to patients with lumbar radicular compression and muscle injury (Wright-
Carpenter 2004, Becker 2007, Chevalier 2009). ACS has been utilized extensively in 
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veterinary medicine predominately in the horse for the management of lameness due to 
synovitis and osteoarthritis. Thomas Weinberger was one of the first veterinarians to use 
ACS and he reported his clinical experience and success using ACS in Germany in 262 
horses treated since 2001 (Weinberger 2008). In a 2007 study, it was estimated that over 
3000 equine patients had received ACS in clinical practice (Frisbie 2007). During a 
review of joint therapy utilized by veterinarians, 54.1% of 791 practitioners stated they 
had experience using autologous conditioned serum as an intra-articular therapy for 
osteoarthritis (Ferris 2011). Of those practitioners who used ACS clinically, 21.9% stated 
frequent use and 32.2% stated occasional use (Ferris 2011). Most commonly, 
veterinarians prescribed ACS when previous attempts to alleviate inflammation in the 
joint with intra-articular corticosteroids were unsuccessful (36.2% of the time) (Ferris 
2011).  Secondarily, ACS was also used when the expense of medication was not a 
limitation for the owner (24.1% of the time) (Ferris 2011). Clinically, most veterinarians 
felt that metacarpo- (metatarso-) phalangeal joint displayed the best response to ACS 
injection (37.3%), however the femorotibial joint (21.6%) and distal interphalangeal joint 
(20.3%) also were highly implicated as showing improvement (Ferris 2011). Finally, the 
study also found that sport horse veterinarians (those that predominately treat horses in 
dressage, jumping, eventing and polo disciplines) were more likely to use ACS than 
veterinarians focused on other disciplines (Ferris 2011). In addition to treatment of 
osteoarthritis, equine surgeons have also used ACS in a prophylactic manner following 
arthroscopic surgery, to provide anti-inflammatory benefit to the joint during the post-
operative rehabilitation period (Textor 2011). 
 
 The early introduction of ACS in North America resulted from a German 
company (Orthogen) marketing a human ACS preparation kit called Orthokine IRAPa for 
use in equine veterinary medicine, following the popularity of ACS in Europe 
(Weinberger 2008). A few years later, a North American company (Arthrex) developed 
an equine specific ACS preparation kit labeled IRAP IIb. Both products have been 
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previously studied in the horse, and shown to increase production of IL-1ra in equine 
serum samples (Frisbie 2007, Hraha 2011). According to a 2009 survey of equine 
practitioners, approximately 54% of respondents had experience using the Orthokine 
IRAPa kit, which was the only ACS product available at the time of survey (Ferris 2011). 
The Orthokine IRAP product has been used for an in vivo investigation (Frisbie 2007), 
whereas, the Arthrex IRAP II product has been studied in an in vitro chondrocyte culture 
(Carlson 2013). One study performed a direct comparison of the two kits and determined 
that both the Orthokine IRAPa and Arthrex IRAP IIb systems increased IL-1ra compared 
to 1-hour control serum (93-fold increase for IRAPa and 119-fold increase for IRAP IIb) 
(Hraha 2011). In recent years it can be argued that use of the Arthrex IRAP IIb product 
has become more common amongst equine veterinarians in North America. This change 
may be a reflection of the modestly improved cytokine profile identified using the 
Arthrex IRAP IIb kit, as reported (Hraha 2011). The Arthrex IRAP IIb kit contains a pre-
made blood collection syringe, butterfly catheter, and a second (closed system) syringe 
that contains beads of borosilicate origin. Borosilicate glass has previously been 
recognized as one of the surfaces that can induce IL-1ra up-regulation from monocytes 
(Meijer 2003). Specifically, the Arthrex IRAP II kit contains 327 borosilicate beads, with 
each bead 3.0 mm in diameter and 92.4 mm2 in surface area (Bare 2010). In comparison, 
approximately 200 borosilicate beads are present within the Orthokine IRAP syringe, 
with each bead 2.5 mm in diameter and 21 mm2 in surface area (Meijer 2003).  
 
 Specific for the Arthrex IRAP II kitb, the process begins by collecting 50 ml of 
whole blood aseptically from the individual equine patient to be treated. The whole blood 
is transferred into a second polypropylene syringe containing the beads, by connecting 
the two syringes by a Leur-lock mechanism. The current recommendation by the 
manufacturer is to hold the syringe at a 60-degree angle and inject the blood slowly, such 
that the blood runs down the wall of the bead-syringe. The bead-syringe is then gently 
inverted a minimum of 10 times to mix the whole blood and beads, and the syringe is 
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placed in a horizontal plane within an Arthrex specific incubatorb. The incubator is set at 
a temperature of 37°C, and the syringe is left untouched for a recommended 16 to 24 
hours (with special care not to exceed 24 hours). Following incubation, the serum is spun 
in an Arthrex specific centrifugeb for 10 minutes at 4000 rpm (which, when taking into 
account the radius of the rotor, equates to approximately 1,800g). Following bead-based 
surface activation, incubation and centrifugation, processed serum is considered 
‘conditioned’ and as such meets the definition of ACS. 
 
 The recommendation for incubation time for the Arthrex IRAP IIb system is likely 
derived from the original description of ACS. Elevation in IL-1ra concentration began at 
30 minutes, and continued to increase for 24 hours. However, after 24 hours of 
incubation, the concentrations then steadily decreased (Meijer 2003). Interestingly, one 
human study utilized an incubation time of only 6 hours, which successfully elevated IL-
1ra when combined with glass beads (Rutgers 2010). Recently, it has been questioned 
whether exposure to glass beads are necessary. This originates from several studies 
wherein IL-1ra concentrations increase in the non-conditioned, yet incubated, control 
serum group (Hraha 2011, Magalon 2014, Fjordbakk 2015). Hraha et. al. postulated that 
exposure to the glass wall of the non-heparinized blood tube, combined with incubation, 
may be the underlying mechanism for the observed increase of cytokine concentrations 
(Hraha 2011). In their study, when concentrations of IL-1ra were compared to 24-hour 
incubated control, the Orthokine IRAPa product (but not Arthrex IRAP IIb) was not 
statistically different. However, both Magalon et. al. and Fjordbakk et. al. reported a 
similar IL-1ra increase in incubated control serum when using plastic (not glass) 
syringes. In fact, both authors proposed that exposure to glass beads may not be 
necessary for preparation of cytokine-rich serum. Since it appears that incubation alone 
influences IL-1ra elevation, further research is required to determine whether glass beads 
may impact other anti-catabolic, catabolic and anabolic proteins, thereby providing 
further therapeutic efficacy via alternate mechanisms. 
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 Under aseptic conditions, the resultant ACS is withdrawn from the IRAP syringe 
using a sterile spinal needle, and aliquoted into individual syringes. During transfer of 
ACS into individual syringes, it is common for ACS to be passed through a 0.2 µm 
micro-filter to help improve the purity of the product during in-house processing. 
Transfer through a micro-filter is also commonly performed a second time, immediately 
prior to intra-articular injection. Aliquots of ACS are generally frozen in a conventional 
freezer at -20°C for future use. To the author’s knowledge, no studies have been 
performed evaluating the effect of freeze-thaw cycles on the composition of ACS in the 
horse, which is important to know since freeze-thaw cycles can induce cell membrane 
rupture and/or protein denaturation (Guo 2013).  
 
 It is important to note that the manufacturer recommends dividing the ACS to 
attain 4 ml aliquots per syringe, but in a clinical setting the volume stored per aliquot is 
predominately dictated by the practitioner. This preference is influenced by the volume 
needed per intra-articular injection, as well as the total volume of ACS attained following 
processing. Although no standard dose for ACS is universally accepted, Weinberger 
reported a treatment protocol based on the type of joint medicated based on his personal 
experience (Table 1.3) (Weinberger 2008).  
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ACS TREATMENT PROTOCOL (ADAPTED FROM WEINBERGER 2008) 
JOINT TREATMENT PROTOCOL 
Coffin Joint Dose: 4 – 6 ml; Number: 2 - 3 times; 
Interval: 8 - 14 days 
Pastern Joint Dose: 2 - 4 ml; Number: 2 - 3 times; 
Interval: 8 - 14 days 
Fetlock Joint Dose: 4 - 6 ml; Number: 2 - 3 times; 
Interval: 8 - 14 days 
Radiocarpal / Intercarpal Joint Dose: 4 - 6 ml; Number: 2 - 3 times; 
Interval: 8 - 14 days 
Elbow Joint Dose: 4 – 6 ml; Number: 2 - 3 times;  
Interval: 8 - 14 days 
Shoulder Joint Dose: 4 - 8 ml; Number: 2 - 3 times; 
Interval: 8 - 14 days 
Tarsometatarsal and Distal Intertarsal Joint  Dose: 1 - 2 ml; Number: 2 - 3 times;  
Interval: 8 - 14 days 
Tibiotarsal Joint Dose: 6 – 8 ml; Number: 2 - 3 times; 
Interval: 8 - 14 days 
Femorotibial / Femoropatellar Joint Dose: 4 - 8 ml; Number: 2 - 3 times; 
Interval: 8 - 14 days 
Coxofemoral Joint Dose: 4 – 8 ml; Number: 2 - 3 times; 
Interval: 12 - 21 days 
 
TABLE 1.3 – ACS treatment protocol developed by Thomas Weinberger for use of IRAP 
for treatment of joint disease in horses (Adapted from Weinberger 2008).  
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 The ideal volume of ACS required to impart the maximal amount of therapeutic 
benefit remains unclear. In normal joints, type B synoviocytes have thousands of IL-1 
receptors present per cell (Larrick 1989). In osteoarthritis, IL-1 receptors are further up-
regulated in the cartilage and synovium (Fernandes 2002). The abundance of IL-1 
receptors increases the likelihood of IL-1 binding, which initiates pro-inflammatory 
change in the joint. Additionally, very minimal IL-1β binding overall is required to 
initiate pro-inflammatory cellular signaling (Fernandes 2002). As such, the quantity of 
IL-1ra that is needed to successfully compete against IL-1 is disproportionally high. The 
disparity in the ratio of IL-1ra to IL-1β has been supported in vitro. During an early 
investigation of IL-1ra, it was found that a 50% reduction in IL-1α could be achieved 
with a 30-fold greater concentration of IL-1ra, while a 50% reduction in IL-1β induced 
prostaglandin E2 could be achieved with a 10-fold greater concentration of IL-1ra 
compared to IL-1 (Arend 1990). Furthermore, this same study also showed that a 100-
fold greater concentration of IL-1ra was required for 50% reduction of IL-1α in hyaline 
cartilage (Arend 1990). With ACS therapy, the ratio of IL-1ra to IL-1 can effectively 
represent therapeutic potential (Meijer 2003). In human medicine, a proposed ratio of 10 
to 1 (IL-1ra to IL-1) has been derived as an ideal threshold for therapeutic efficacy 
(Granowitz 1991). However, to date, no calculations of the ideal IL-1ra to IL-1 ratios 
have been investigated for veterinary species. When comparing the IL-1ra to IL-1β ratio 
of Orthokine IRAPa and Arthrex IRAP IIb kits, only the IRAP IIa kit (with a ratio of 6:1) 
had a statistically higher ratio than that of 1-hour serum control (Hraha 2011). Hraha et 
al. recognized that the equine IL-1ra to IL-1 ratio they found was low compared to 
human-derived ACS (Hraha 2011). 
  
 Another unique consideration of ACS joint therapy is the inability to standardize 
the consistency of the product, such as is accomplished with traditional pharmaceutical 
drugs. This unpredictability is most apparent when appreciating the high standard of error 
of reported IL-1ra concentrations in prior equine ACS studies (Frisbie 2007, Hraha 2011, 
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Fjordbakk 2015). Since ACS is derived from individual horses, inherent variability exists 
between horses and within the same horse after exposure to external factors, such as 
stress (Fjordbakk 2015).  Fjordbakk et. al. studied the impact of surgery, as determined 
by serum amyloid A (SAA) concentration, on resultant cytokine production in equine 
ACS. Horses classified with ‘marked’ stress (SAA > 200 mg/L) had significantly lower 
concentrations of IL-1ra, TGF-β, and IGF-1 than those horses classified with ‘moderate’ 
or ‘mild’ stress (SAA < 200mg/L) (Fjordbakk 2015). Potentially, an influence of 
systemic OA severity could also influence IL-1ra production in ACS. However, to the 
author’s knowledge, no studies have explored this concept. 
 
 Within the ACS product, IL-1ra is marketed as the major anti-inflammatory factor 
present. However, other biologically active proteins change in concentration. Increases in 
anti-catabolic and anabolic proteins such as IL-10 (Meijer 2003, Rutgers 2010, Magalon 
2014), IL-4 (Meijer 2003), and TGF-β (Rutgers 2010) have been reported in human ACS. 
Hraha et. al. evaluated both Orthokine IRAPa and Arthrex IRAP IIb systems with equine 
blood, and found increased concentrations of IL-10, TGF-β, and IGF-1 in both kits 
(compared to unincubated serum). In conflict with these findings, Fjordbakk et. al. found 
no difference in IL-10, TGF-β, and IGF-1 in equine ACS. However, this study also 
utilized a human and a proprietary, unmarketed ACS kit, rather than the prevalent 
Orthokine IRAPa and Arthrex IRAP IIb systems.  
 
 Also of importance is whether conditioning of serum may increase pro-
inflammatory cytokines. In the original description of the Orthokine IRAPa kit using 
human blood, no increase in the pro-inflammatory cytokines IL-1β or TNF-α were 
reported (Meijer 2003). Contrary to these findings, both Rutgers et. al. and Magalon et. 
al. have identified significant increases in IL-1β, TNF-α, and the immuno-modulatory 
cytokine IL-6  in human ACS (Rutgers 2010, Magalon 2014).  Using equine blood, both 
IL-1β and TNF-α were elevated in the Orthokine IRAPa and Arthrex IRAP IIb systems 
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compared to unincubated control (Hraha 2011). Yet, Fjordbakk et. al. could only identify 
an increase in IL-1β, but not TNF-α, in their study (Fjordbakk 2015). Understanding of 
the anti- and pro-inflammatory biological spectrum of ACS remains conflicted. This 
disagreement may be a cumulated result of variability between sample populations, 
differences in species, differences in ACS kits utilized, or varying laboratory methods. 
Further research to define the actual composition of ACS is needed, to help better 
understand how it works. 
 
 Assessment of clinical efficacy from ACS treatment for osteoarthritis has 
conflicting opinions in the human medical field. In a prospective, non-blinded, clinical 
trial treating patients with hip osteoarthritis (n = 46 patients) with ACS, therapy was more 
effective when administered alone in reducing pain scores when compared to ACS/ 
corticosteroid combination and ACS/corticosteroid/recombinant IL-1ra combination 
(Baltzer 2013). Another prospective, randomized, patient/observer blinded, placebo-
control clinical trial was performed on patients with knee osteoarthritis (n = 376 patients) 
(Baltzer 2009). In this study, ACS was found to reduce clinical symptoms and pain scores 
for up to 6 months, when compared to hyaluronic acid (HA) and saline controls (Baltzer 
2009). However, a major flaw in the study design was that ACS patients received 6 intra-
articular injections total, whereas HA and saline patients only received 3 (Baltzer 2009). 
A separate group performed another prospective, randomized, patient/observer blinded 
clinical trial that also used knee osteoarthritis (n = 167 patients) (Yang 2008). In this 
study, outcome was based on a variety of established pain scales. Although ACS treated 
patients trended towards more comfort and improved joint function, no parameters 
measured were statistically significant (Yang 2008).  
 
 In horses, a limited amount of peer-reviewed, scientific research is available to 
help understand ACS therapy. One in vitro study collected cartilage from cadavers, which 
were in turn transformed into chondrocyte pellets and then exposed to either IL-1β and 
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ACS, or IL-1β and unconditioned serum (Carlson 2013). In this experiment, no 
significant changes were identified when evaluating glycosaminoglycan release, total 
glycosaminoglycan concentration, MMP-3 concentration, total DNA content, or mRNA 
expression of cyclo-oxygenase-2, aggrecan and type II collagen (Carlson 2013). The 
concentration of IGF-1 was identified as significantly higher in the ACS-treated pellets, 
which was interpreted as a beneficial effect. The authors concluded that very minimal 
difference with ACS exposure occurred (Carlson 2013).	  	  	  
	  
 Only one in vivo ACS study has been performed using horses, thus far. As such, 
this individual clinical investigation has become a noteworthy scientific basis to justify 
ACS use in equine veterinary practice. In 2007, Frisbie et al. used an osteochondral 
fragment model for induction of osteoarthritis in the middle carpal joint (Frisbie 2007). 
Eight horses had one forelimb induced with an osteochondral fragment and the 
contralateral joint sham operated (treatment group). For therapy intervention, 6 ml of 
ACS (Orthokine IRAPa kit) was administered into the osteochondral fragment joint while 
saline was injected into the sham-operated joint. A second group of eight placebo horses 
also underwent surgery (one limb for osteochondral fragmentation, other only sham 
operated) and were subsequently treated with placebo. Injections were started on day 14 
of the study, and repeated once per week for a total of 4 weeks (Frisbie 2007). Several 
outcome measures were evaluated at various time points, including lameness grading 
(including flexion stress tests), radiographic evaluation, synovial fluid analysis (gross 
characteristics, white blood cell count/differential, total protein concentration, mucin 
content, glycosaminoglycan [GAG] concentration, prostaglandin-E2 [PGE2], IL-1ra 
concentration), synovial membrane gross pathology/histology, cartilage gross 
pathology/histology, and cartilage matrix metabolism analysis (Frisbie 2007).  
 
 Clinically, a statistically significant improvement in the degree of lameness was 
subjectively noted 35 days following the last intra-articular ACS injection. However, this 
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improvement was only identified at one single time point. Also of interest, the 
improvement in lameness was less than one full grade (based on American Association of 
Equine Practitioner scale [Anonymous 1991]) in magnitude (Frisbie 2007). It is unclear 
how the OA and sham operated limbs were evaluated independently. A more objective 
lameness analysis (ie, force plate) may have improved the strength of lameness 
observation.	  Other subjective assessments of clinical improvement, such as joint effusion 
and joint flexion response, were unchanged (Frisbie 2007). Radiographic changes of 
osteoarthritis became apparent using the carpal osteochondral fragment model; however, 
no improvements in radiographic signs were seen in the ACS-treated group when 
compared to controls (Frisbie 2007).	  Additionally, when examining the synovial fluid for 
IL-1ra concentrations, the investigators combined the IL-1ra concentrations from the OA 
and sham operated joints, and demonstrated a significant elevation in IL-1ra compared to 
the placebo horse group when measured 35 days after the last ACS injection (Frisbie 
2007). It remains unclear why both the OA and sham operated joints were evaluated 
together, and not assessed individually. After combining the two joints, the authors then 
inferred that administration of exogenous IL-1ra (via ACS) may potentially stimulate 
endogenous, systemic IL-1ra production (Frisbie 2007).  
	  
	   In this study, there was no significant difference in neutrophil percentage of the 
total white blood cell population, total protein concentration, GAG concentration, or 
PGE2 concentration found between groups (Frisbie 2007). Scores for gross cartilage 
erosion and synovial membrane hemorrhage were assigned, and although ACS-treated 
joints displayed a trend for improved (lower) scores, this outcome was not statistically 
significant (Frisbie 2007). Histologically, there was a significant decrease in intimal 
hyperplasia in the ACS-treated joints; however, grades of subintimal fibrosis, synovial 
vascularity, and cartilage erosion/fibrillation showed no difference between groups 
(Frisbie 2007). Finally, no significant difference in cartilage GAG content from 
metabolism was present between groups (Frisbie 2007). Although many parameters 
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showed no statistical difference, based on the improved lameness the authors concluded 
that IL-1ra showed promise as an intra-articular therapy (Frisbie 2007). 
 
 It is unknown how long exogenous IL-1ra remains in the joint following injection. 
Repeated doses of ACS are commonly administered when treating OA. The justification 
for serial doses is unclear, however may originate from treatment protocols that use 
recombinant IL-1ra, wherein several doses are required for therapeutic efficacy (Gouze 
2003). Baltzer et. al. administered 2 doses of recombinant IL-1ra per week for 3 weeks (6 
total doses) (Baltzer 2009). Rapid intra-articular clearance of IL-1ra occurs within 3 days 
following intra-articular ACS injections, which may justify repeated dosing (Rutgers 
2010). Veterinarians commonly administer 3 to 5 doses, with each dose separated by 7 to 
14 day intervals (Weinberger 2008, Textor 2011). In the Frisbie et. al. study, the authors 
developed their treatment protocol (4 doses, 7 days apart) based on common use of the 
medication in Europe (Frisbie 2007). The availability of large volumes of ACS from one 
individual ACS kit readily allows veterinarians to repeat intra-articular injections.  
 
 ACS is marketed as a novel therapy that is more biologic than traditional 
pharmaceuticals. Due to it autologous and biological composition, there is the added 
bonus that ACS cannot be detected by conventional drug testing. This becomes an 
important advantage for many owner/trainer and veterinarian teams that are actively 
managing OA in athletic horses that compete in regulated disciplines. By definition, ACS 
therapy is categorized as a medical device. Although medical devices can provide 
alternative means for therapy, there is no requirement for safety or efficacy evaluation. In 
fact, the American Association of Equine Practitioner (AAEP) guidelines maintain that if 
an approved pharmaceutical product exists for a specific disease, the pharmaceutical 
should be used instead. Additionally, AAEP states that it is unethical to promote a 
medical device as equivalent to an approved pharmaceutical, and clients must be 
informed of the difference between the two products prior to therapy (Anonymous 2010). 
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The economic implication of offering ACS therapy is favorable for veterinarians. The 
average wholesale cost of each individual ACS kit is around $250. When combined with 
the professional costs for intra-articular injection and repeated dosage, the total cost of 
ACS often totals $1000 to $1200 (Textor 2011). In comparison, intra-articular 
corticosteroids may be a third to a quarter of this price. 
 
 In spite of increased ACS usage in horses, no prospective or retrospective 
evaluations of short and long term clinical use has been published to date (Ferris 2011, 
Textor 2011). Anecdotally, many practitioners regard the medication as safe, with the 
same risk for joint inflammation (flare) or infection as other intra-articular medications. 
Practitioners apparently do not commonly mix antibiotics with ACS when injecting the 
serum into a joint. The effects of adding antibiotics on ACS composition are unknown. 
Maintenance of ACS product sterility is almost solely dependent on those handling it. To 
the author’s knowledge, no adverse systemic effects (such as those seen with non-
steroidal anti-inflammatories or corticosteroids) have been associated with ACS. 
 
 The clinical benefits of IL-1ra have been previously demonstrated by 
administering recombinant IL-1ra intra-articularly or using gene therapy as a method of 
increasing concentrations  (Caron 1996, Frisbie 2002). To date, rationale for ACS use in 
horses is limited to one in vivo study, which was funded by the manufacturer (Frisbie 
2007). Anecdotal evidence from practitioners suggests that the therapy may be effective 
in reducing OA pain. Detailed knowledge of the composition of ACS and its effect on 
arthritic joints need to be defined. A better understanding of the variability of the product 
from horse to horse, the ratio of IL-1ra to IL-1β required for efficacy, influence of glass 
beads and incubation on conditioning of serum, and validation of repeated doses would 
provide better scientific rationale for treatment. Well-designed clinical trials are 
necessary to validate therapeutic use of ACS. 
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CHAPTER 2: 
HYPOTHESIS, SPECIFIC AIMS, AND RATIONALE 
 
 
PART A - HYPOTHESIS 
 
 
 Our central hypothesis is that autologous conditioned serum (ACS) will be 
associated with anti-inflammatory effects when injected into osteoarthritic distal 
interphalangeal joints. The main objectives of this study are: (1) to evaluate the cytokine, 
MMP, and TIMP content of ACS produced by the Arthrex® IRAP II systemb and (2) to 
measure cytokine, MMP, and TIMP content of osteoarthritic distal interphalangeal joint 
synovial fluid 7 days following three repeated intra-articular ACS injections.  
 Aliquots of ACS are usually frozen for use at a later date. However, the effect of 
freeze-thaw cycle on ACS is unknown. It is unknown whether repeated doses are more 
effective than a single dose. Clinical improvement of osteoarthritis following intra-
articular ACS therapy has not been documented under controlled conditions. 
 Our working hypothesis is that ACS will have increased anti-inflammatory 
cytokines and tissue inhibitors of metalloproteinases, with smaller increases in pro-
inflammatory cytokines and matrix metalloproteinases, when compared to unconditioned 
1-hour serum. We also hypothesize that injection of ACS into osteoarthritic distal 
interphalangeal joints will be associated with increased synovial fluid concentrations of 
anti-inflammatory cytokines and tissue inhibitors of metalloproteinases, in greater 
proportion to changes seen in pro-inflammatory cytokines and MMPs, when compared to 
synovial fluid prior to ACS injection. We hypothesize that high variability in ACS 
composition will exist between individual horses, that repeated dosing will result in 
greater increases in anti-inflammatory biomarkers compared to that of a single dose, and 
that all biomarker concentrations in ACS will decrease following an additional freeze-
thaw sample. We hypothesize that clinical improvement in lameness will be present 
following ACS therapy. Knowledge gained from this study may lead to future studies on 
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the efficacy of ACS for treatment of osteoarthritis in horses.  
PART B -  SPECIFIC AIMS 
1. Define the cytokine, matrix metalloproteinase, and tissue inhibitor of metalloproteinase 
content of ACS produce from the commercially available Arthrex® IRAP IIb system. 
2. Evaluate variability in cytokine, matrix metalloproteinase, and tissue inhibitor of 
metalloproteinase concentrations in ACS between individual horses.  
3. Evaluate the effect of freeze-thaw cycle on ACS composition. 
4. Evaluate whether repeated (serial) doses of ACS will further increase anti-
inflammatory biomarker concentrations in synovial fluid, compared to concentrations 
after a single dose of ACS. 
5. Evaluate improvement of lameness grade following intra-articular ACS therapy in 
cases of naturally occurring osteoarthritis. 
6. Validate/refute that intra-articular injection of ACS into an osteoarthritic joint will 
result in increased synovial fluid concentrations of anti-inflammatory cytokines and 
tissue inhibitors of metalloproteinases, with minimal concurrent changes in matrix 
metalloproteinase or pro-inflammatory cytokine concentrations. 
 
 
 40 
 
PART C -  RATIONALE 
 The rationale for this study is that in spite of the common clinical usage of ACS, 
little is known about the actual composition of the product injected into the horse, how 
much ACS varies from horse to horse, or the effects of freeze-thaw cycles on ACS 
composition. Additionally, knowledge regarding any change to the composition of 
cytokines, MMPs and TIMPs in synovial fluid after treatment, or whether any clinical 
improvement occurs after intra-articular ACS therapy, also remains unknown. Given the 
popularity of ACS in equine veterinary medicine, there is clearly a need for more 
scientific information regarding the clinical use of ACS in horses.  
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CHAPTER 3: 
MATERIALS AND METHODS 
 
 
PART A -  POWER CALCULATIONS 
 
 To determine the number of horses required for the study, power calculations 
were based on changes demonstrated in our pilot data (Table 3.1 and 3.2). Eight analytes 
listed in Tables 3.1 and 3.2 that were either significantly different between groups 
(normal vs. osteoarthritic synovial fluid or serum) or approached significance (P<0.3) 
were used to determine power. Unpaired means were compared between two groups 
(normal vs. osteoarthritis) for each analyte. Differences between the means were assumed 
to be the true difference. Standard deviations between two groups (normal vs. 
osteoarthritis) of each analyte were averaged. Then, sample size required to detect a 
difference for each analyte was calculated, with power set at 80%. Finally, averaging the 
previously calculated sample sizes across the 8 analytes set the total number of horses 
required for the study.  Therefore, for this investigation, 12 horses were required to 
achieve 80% power at an alpha of P<0.05. 
 
	  
SF IL-1β IL-1ra TNFα IL-4 IL-6 IL-8 IL-10 
Norm 
N=4 
0.10 *  
±0.14 
33.4 
±26.6 
0.00 † 
±0.01 
1.47 
±1.47 
0.20 
±0.28 
17.1 † 
±21.4 
0.09 † 
±0.05 
OA 
N=7 
0.62 
±0.46 
60.4± 
73 
0.56 
±0.69 
1.23 
±1.41 
0.22 
±0.53 
2.1 ±4.3 0.05 ±0.04 
Serum 
Norm 
N=3 
0.55 
±0.95 
47.2 † 
± 45 
0 ± 0 0 ± 0 0 ± 0 2730 
±884 
0 ± 0 
OA 
N=4 
1.03 
±1.03 
113.2 
±80 
0.25 
±0.29 
0 ± 0 0.64 
±1.29 
1628 
±208 
0.11 ±0.23 
 
TABLE 3.1 - Pilot multiplex assay data for cytokines and growth factors using 
commercially available human kits (R&D Systemsc). Mean (±SD) concentrations from 
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synovial fluid (carpi) and serum from normal (Norm) horses and those with naturally 
occurring OA associated with osteochondral injury (OA). Note: Pilot assays used 
polystyrene beads, whereas magnetic beads were used for the subsequent ACS 
investigation. Significant differences and trends are bolded. * P<0.05, † P<0.3. 
 
 
SF MMP3 MMP9 MMP13 TIMP1 TIMP3 TIMP4 
Norm 
n=4 
709 ±252 296 ±332 0 ± 0* 207 ±9.4 1499 † 
±439 
15.2 * 
±1.17 
OA 
n=7 
923 ±385 259 ±425 39.6 ±56.9 212 ±7.6 1062 ±484 19.8 ±2.7 
Serum 
Norm 
N=3 
192 † 
±102 
186949 
±106405 
0 ± 0 - - - 
OA 
N=4 
95 ±45.1 95269 
±47410 
0 ± 0 - - - 
 
TABLE 3.2 - Pilot multiplex assay data for MMPs and tissue inhibitors of 
metalloproteinases (TIMPs) using commercially available human kits (R&D Systemsc). 
Mean (±SD) concentrations from synovial fluid (carpi) and serum from normal (Norm) 
horses and those with naturally-occurring OA associated with osteochondral injury (OA). 
Note: Pilot assays used polystyrene beads, whereas magnetic beads were used for the 
subsequent ACS investigation. Significant differences and trends are bolded. * P<0.05, † 
P<0.3	  
 
 
PART B -  STUDY DESIGN 
 
 Client-owned horses with unilateral forelimb distal interphalangeal (DIP) joint 
osteoarthritis (OA) were identified. For inclusion, horses needed to satisfy at least 3 of 
the following criteria: palpable DIP joint effusion, positive response to distal limb 
flexion, positive response to DIP joint intra-articular analgesia, radiographic evidence of 
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OA in the DIP joint, and/or previous positive response to intra-articular corticosteroid 
injection. Three blinded investigators (T.N.T., N.S.E., M.C.M.) graded radiographs for 
severity of DIP OA and changes to the navicular bone (Manfredi 2012), using a modified 
scheme (Table 3.3 and 3.4). Exclusion criteria included horses with moderate to severe 
radiographic signs of navicular bone abnormalities (≥ grade 3 on Table 4) or history of 
previous corticosteroid injection in the affected joint within 6 months. 
 
0 Normal appearance of distal interphalangeal joint 
1 Small osteophyte present in either dorsal or palmar aspect of joint 
2 Small osteophytes present in both dorsal and palmar aspect of joint 
3 Moderate or large sized osteophytes present, presence of subchondral lucencies 
4 Joint collapse, cyst formation in articular surface of P2 or P3 
 
TABLE 3.3 – Radiographic grading scale for distal interphalangeal osteoarthritis. The 
average measure intraclass correlation coefficient for agreement of the observers’ distal 
interphalangeal joint radiographic scores in this study was 0.89 (≥ 0.80 is considered 
acceptable). 
 
0 Normal appearance of navicular bone 
1 Multiple distal border lucencies of variable shapes 
2 Sclerosis mildly obscuring corticomedullary junction 
3 Poor corticomedullary junction, thick cortices,  
large enthesophytes, distal border fragments 
4 Large cysts, productive bone on flexor surface 
 
TABLE 3.4 – Radiographic grading scale for navicular bone pathology. The average 
measure intraclass correlation coefficient for agreement of the observers’ navicular bone 
radiographic scores was 0.95 (≥ 0.80 is considered acceptable). 
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 On the day prior to first intra-articular ACS injection, 50 ml of blood was 
collected aseptically via jugular venipuncture into an ACS syringe containing borosilicate 
beadsb, following manufacturer directions. The syringe was incubatedb at 37°C for 19 
hours (range: 18-20 hours), then centrifugedb for 10 minutes at 1,800 x g. This 
conditioned serum (ACS) was aseptically aspirated from the syringe, and passed through 
a 0.2 µm filterd into three separate 5 ml aliquots that were used for weekly intra-articular 
treatments as described below. Any remaining ACS (range: 3-10 ml) was further 
aliquoted and frozen at -80°C for future analysis. Day 0 aliquot was injected 
immediately, but day 7 and 14 doses were stored frozen (-20°C) and thawed prior to 
administration. As a control, an additional 20 ml of blood was simultaneously collected 
in non-heparinized vacuum tubes. Ten ml were immediately centrifugede for 10 minutes 
at 1,800 x g, and serum decanted within 1 hour following venipuncture (baseline control 
– 1-hr serum). The remaining 10 ml was incubatedb at 37°C for 18-20 hours, and 
similarly centrifugede. Serum was decanted within 19 hours of venipuncture, similar to 
ACS, and was used as an incubated, unconditioned control (19-hr serum). Control serum 
was aliquoted and frozen at -80°C for future analysis. 
 
 For each horse, arthrocentesis of the OA-affected DIP joint was performed on day 
0, 7, 14, and 21, with day 0 serving as pre-treatment OA baseline. Horses were sedated 
with detomidine hydrochloridef (0.004 – 0.02 mg/kg IV), and a lateral and medial abaxial 
sesamoid nerve block was performed with 2 ml of lidocaineg per palmar digital nerve. 
The DIP joint was graded for effusion (mild, moderate, or severe), and then aseptically 
prepared for dorsal and lateral approaches (Moyer 2011). To obtain synovial fluid, a 20-
gauge, 1.5-inch needle was inserted into the DIP joint using a dorsal approach initially, 
followed by a lateral approach if necessary. Arthrocentesis occurred during late morning 
to early afternoon for all horses over all sampling periods. Number of attempts required 
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to obtain fluid, as well as presence/absence of blood contamination was documented for 
each collection. Synovial fluid was centrifugede for 10 minutes at 2,500 x g and decanted 
if blood contamination was present; aliquots were frozen at -80°C for future analysis. 
 
 On days 0, 7, and 14, immediately following arthrocentesis, a 5 ml aliquot of 
fresh ACS (day 0) or thawed ACS (days 7 and 14) was again passed through a 0.2 µm 
filterd, and 4 ml of ACS injected into the DIP joint. For days 7 and 14, the remaining 1 ml 
of ACS was refrozen a second time (at -80°C) for future laboratory analysis. On day 21, 
no ACS was injected; only arthrocentesis was performed to assess previous ACS 
treatments. Throughout the study, horses were maintained on strict stall rest with no 
exercise allowed. No anti-inflammatory medications or joint supplements were given. 
 
 At each time point (day 0, 7, 14, and 21), prior to arthrocentesis, horses were 
videotaped walking and trotting in a straight line, on a hard surface. Additionally, 
bilateral distal forelimb flexions were performed. At study completion, three blinded 
investigators (T.N.T., N.S.E., M.C.M.) graded the lameness videos based on the 
American Association of Equine Practitioners scale of lameness (Anonymous 1991). 
Median scores were used for analysis. 
 
PART C -  ELISA AND MULTIPLEX METHODOLOGY 
 
 Serum and synovial fluid samples were evaluated using an equine specific 
ELISAc (IL-1ra) or human multiplex assaysc using Luminex® xMAP® technologyh to 
evaluate cytokine (IL-1β, -4, -6, -8, -10 and TNFα), matrix metalloproteinase (MMP-1, -
3, -9, and -13) and tissue inhibitor of MMP (TIMP-1, -2, -3, and -4) concentrations. For 
human multiplex assays, magnetic beads (rather than polystyrene beads) were chosen. All 
samples were run in duplicate or triplicate at pre-determined dilutions based on pilot 
studies (Table 3.1 and 3.2) where partial validation was performed with equine serum and 
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synovial fluid to demonstrate that each analyte could be recognized in each equine fluid 
(unpublished data). Equine and human sequences have the highest percent homology 
overall (>60% homology required for potential cross-reactivity with cytokines 
[Scheerlinck 1999]), making human commercial kits the best option for identifying 
cytokines in equine fluids (Table 3.5).  Both the equine specific ELISAc and the human 
multiplex assaysc were run according to manufacturer recommendations, with no 
alterations in laboratory technique.  
 
 The ELISA used is sandwich type, as it utilizes a capture antibody immobilized 
within the plate wells to bind the analyte of interest (ie, IL-1ra). Binding of detection 
antibody to the analyte of interest then provides fluorescence that can be measured as 
mean absorbance by a plate reader. When compared against a standard curve, quantitative 
results are available. The Luminex platform technology is a bead based, flow cytometer 
system that can evaluate up to 100 different analytes attained from a single sample of 
fluid. Each bead is internally color-coded with varying ratios of 2 fluorescent dyes. This 
allows an analyte of interest to be measured through covalent coupling to specific capture 
antibodies. One laser identifies the specific bead set, and another laser quantifies the 
florescent reaction to the antibody. Then, the florescent reaction can be compared against 
a standard curve (similar to an ELISA), to also provide quantitative results. 
 
 Because values in some samples were below the lower limit of quantification 
(LLOQ - lowest standard curve point) for multiple analytes (Table 3.6), half of the lower 
limit of detection for each individual analyte was used as the representative concentration 
to allow statistical analyses (Croghan 2003). Mean intra-assay and inter-assay coefficient 
of variation (CV) for IL-1ra was 9% and 8%, respectively, whereas the remaining 
analytes measured by multiplex assay averaged 8% and 12%, respectively.  
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Protein Equine NCBI 
Accession # 
 
% Human 
protein 
homology 
 
Human 
accession # 
 
% Mouse 
protein 
homology 
 
Mouse 
accession # 
 
% Rat 
protein 
homology 
 
Rat 
accession # 
 
IL-1 β 
 
AAC39256 
 
65 
 
EAW73607 
 
62 
 
NP_032387 
 
60 
 
NP_113700 
 
IL-1 Ra NP_001075994 77 NP_776213 
isof 2 
76 NP_112444 
isof 1 
 
75 
 
NP_071530 
 
IL-4 
 
NP_001075988 
 
55 
 
CAP72493 
 
40 
 
BAD83771 
 
43 
 
NP_958427 
 
IL-6 
 
NP_001075965 
 
61 
 
NP_000591 
 
43 
 
AAA68814 
 
44 
 
NP_036721 
 
IL-8 
 
NP_001077420 
 
72 
 
CAA77745 
 
    
IL-10 
 
NP_001075959 
 
84 
 
CAG46825 
 
75 
 
NP_034678 
 
76 
 
NP_036986 
 
TNF α 
 
NP_001075288 
 
85 
 
NP_000585 
 
77 
 
NP_038721 
 
75 
 
CAA47146 
 
MMP-1 
 
NP_001075316 
 
86 
 
AAV38949 
 
59 
 
NP_114395 
 
59 
 
NP_001128
002 
 
MMP-2 CAB46656 
 
95 
 
BAG35588 
 
94 
 
NP_032636 
 
94 
 
CAA50583 
 
MMP-3 
 
AAB05774 
 
81 
 
NP_002413 
 
73 
 
NP_034939 
 
71 
 
EDL78534 
 
MMP-9 
 
ABU80399 
 
84 
 
P14780 
 
78 
 
BAA02208 
 
77 
 
EDL96479 
 
MMP-13 
 
NP_001075273 
 
90 
 
AAH67523 
 
86 
 
NP_032633 
 
86 
 
P23097 
 
TIMP-1 
 
NP_001075984 
 
82 
 
BAG52016 
 
66 
 
NP_0010378
49 
 
71 
 
AAB08483 
 
TIMP-2 
 
ABL11344 
 
98 
 
AAC50729 
 
100 
 
AAA40446 
 
100 
 
AAA21553 
 
TIMP-3 
 
CAB51854 
 
99 
 
NP_000353 
 
96 
 
NP_035725 
 
95 
 
NP_037018 
 
TIMP-4 
 
XP_001492627 
Predicted 
90 
 
AAB40391 
 
84 
 
NP_542370 
 
84 
 
NP_001102
863 
 
 
 
TABLE 3.5 - Homology of equine cytokine, MMP, and TIMP protein sequences 
compared to human, mouse, and rat (determined using NCBI BLASTp software). Note 
that equine and human sequences have the highest percent homology overall (>60% 
homology required for potential cross-reactivity with cytokines [Scheerlinck 1999]), 
making human commercial kits the best option for identifying cytokines in equine fluids. 
 
 
 48 
 
Please note that homology alone does not indicate whether equine proteins will interact 
with human-based assays, but provided the starting point as to which species to use.  Pilot 
data with pooled serum and synovial fluid from horses was performed by the 
investigators (unpublished data) to partially validate use of human assays with equine 
matrices (precision, linearity of dilution, parallelism, percent recovery, and stability). 
Note that MMP-2 did not reliably react with either equine fluid and as such was not 
examined in this study.  
 
 
BIOMARKER 1 
HOUR 
19 
HOUR 
ACS D0 SF D7 SF D14 SF D21 SF 
IL-1ra 0 / 11 0 / 11 0 / 11 0 / 11 0 / 11 0 / 11 0 / 11 
IL-1β 2 / 11 0 / 11 2 / 11 7 / 11 7 / 11 6 / 11 7 / 11 
TNFα 3 / 11 1 / 11 4 / 11 7 / 11 7 / 11 9 / 11 7 / 11 
IL-4 3 / 11 1 / 11 9 / 11 9 / 11 10 / 11 10 / 11 11 / 11 
IL-6 4 / 11 2 / 11 8 / 11 8 / 11 11 / 11 9 / 11 10 / 11 
IL-8 0 / 11 0 / 11 0 / 11 0 / 11 1 / 11 1 / 11 0 / 11 
IL-10 6 / 11 3 / 11 8 / 11 7 / 11 9 / 11 9 / 11 7 / 11 
MMP-1 0 / 11 0 / 11 0 / 11 0 / 11 0 / 11 0 / 11 0 / 11 
MMP-3 0 / 11 0 / 11 0 / 11 0 / 11 0 / 11 0 / 11 0 / 11 
MMP-9 0 / 11 0 / 11 0 / 11 0 / 11 0 / 11 0 / 11 0 / 11 
MMP-13 11 / 11 11 / 11 11 / 11 4 / 11 3 / 11 7 / 11 4 / 11 
TIMP-1 0 / 11 0 / 11 0 / 11 0 / 11 0 / 11 0 / 11 0 / 11 
TIMP-2 0 / 11 0 / 11 0 / 11 0 / 11 0 / 11 0 / 11 0 / 11 
TIMP-3 0 / 11 0 / 11 0 / 11 0 / 11 0 / 11 0 / 11 0 / 11 
TIMP-4 0 / 11 0 / 11 0 / 11 0 / 11 0 / 11 0 / 11 0 / 11 
 
TABLE 3.6 - Description of the number of samples that were measured below the lower 
limit of quantification for all analytes in serum and synovial fluid. (1 HOUR = 
unincubated serum control; 19 HOUR = incubated serum control; ACS = autologous 
conditioned serum; D0 SF = Day 0 synovial fluid sample; D7 SF = Day 7 synovial fluid 
sample; D14 SF = Day 14 synovial fluid sample; DAY 21 SF = Day 21 synovial fluid 
sample). 
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PART D -  STATISTICAL ANALYSIS 
 
 Serum and synovial fluid concentrations of each analyte were assessed using 
Shapiro-Wilk normality test to determine appropriate analysis for each individual analyte. 
In serum, parametric data was compared using one-way ANOVA, with Tukey’s post-hoc 
multiple comparisons for IL-1ra, IL-8, MMP-1 and -9, TIMP -1, -2, -3, and -4; non-
parametric data was compared using Kruskal-Wallis with Dunn’s post-hoc multiple 
comparisons for IL-1β, -4, -6, and -10, TNFα, MMP-3 and -13. MMP:TIMP ratios in 
serum were assessed similarly, with normality of individual ratios detailed in Figure 4.3. 
All analytes in synovial fluid were non-parametric and were assessed using the Friedman 
test, with Wilcoxon signed-rank test for post-hoc multiple comparisons. Percent change 
calculations (ie, [[x2 – x1]/[x1]*100]) was used to facilitate identifying trends of increase 
or decrease in synovial fluid analytes.  
 
 Coefficient of variation was calculated to determine variability in biomarker 
concentrations in ACS between horses, as well as determine precision of assays. Average 
measures intra-class correlation coefficient was used to evaluate reliability of lameness 
and radiographic grades among clinicians. Spearman rank tests were used to assess 
correlations between arthrocentesis attempts, blood contamination, joint effusion, 
lameness grades, radiographic scores, and all analytes to determine any confounding 
variables and/or relationships with disease severity on clinical response to ACS. 
Significance was set at P<0.05 for all analyses. 
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CHAPTER 4: 
RESULTS 
 
 
PART A -  POPULATION AND INCLUSION 
 
 Eleven horses met inclusion criteria and were recruited for the study. Study 
population included mean (±SD) age of 16.9 years (±4.4), weight of 540 kg (±55), and 
height of 159.3 cm (±6.6). Breeds included Thoroughbred (4), Quarter Horse (3), 
Warmblood (2), and American Paint Horse (2), with 6 mares and 5 geldings. The affected 
limbs included 10 right and 1 left fore.  
 
 All horses (11/11) had palpable DIP joint effusion and responded to distal limb 
flexion. Radiographic signs of DIP joint OA (as based on blinded review – Table 3.3) 
were present in 8/11 horses. Of these eight horses, six (6/8) were determined as grade 1, 
one (1/8) as grade 2, and one (1/8) as grade 3. Of the three horses without radiographic 
DIP OA, two (2/3) responded to intra-articular analgesia and one (1/3) had previously 
responded favorably to a corticosteroid injection. When assessing for changes to the 
navicular bone (as based on blinded review – Table 3.4), six horses (6/11) were deemed 
normal, four horses (4/11) classified as grade 1, and one horse as grade 2 (1/11). An 
intra-articular DIP joint block improved the lameness by >50% within 10 minutes in 6/11 
horses, whereas 5/11 horses had a previous improvement in lameness noted after intra-
articular corticosteroid administration.  
 
PART B -  SERUM 
 
 ACS and 19-hr control serum were incubated for a mean (±SD) of 19 hours (±51 
min). Fifty ml of whole blood resulted in 20.2 (±2.3) ml of total ACS product. Median 
number of arthrocentesis attempts was 1, with 39 of 44 synovial fluid samples having 
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blood contamination (Table 4.1). At sampling times (n=44), effusion was graded as 
absent (2), mild (35), and moderate (7) (Table 4.2).  
	  
SAMPLING Day 0 Day 7 Day 14 Day 21 
Mean Arthrocentesis Attempts 1.6 1.2 1.4 1.4 
Blood Contamination YES 9 YES 10 YES 9 YES 11 
NO 2 NO 1 NO 2 NO 0 
	  
TABLE 4.1 – Representation of the mean arthrocentesis attempts for arthrocentesis and 
the presence of blood contamination within synovial fluid samples on days 0, 7, 14, and 
21. 
	  
EFFUSION Day 0 Day 7 Day 14 Day 21 
Absent 0 0 1 1 
Mild 7 8 10 10 
Moderate 4 3 0 0 
Severe 0 0 0 0 
	  
TABLE 4.2 – Representation of the degree of effusion, subjectively graded as absent, 
mild, moderate, or severe within DIP joints on days 0, 7, 14, and 21. 
 
 Median IL-1ra concentration in ACS was 36 times higher (P<0.0001) than 1-hr 
control serum, but was not significantly different from 19-hr control serum (Figure 4.1). 
Median IL-1ra to IL-1β ratio in ACS was significantly higher compared to 1-hr 
(p=0.011), but not 19-hr control serum (Figure 4.1). ACS contained significantly less IL-
4 and IL-8 compared to 1-hr and 19-hr serum controls, whereas IL-6 was significantly 
lower in ACS compared to 19-hr serum control (Figure 4.1). MMP-1 and MMP-9 were 
significantly elevated in ACS compared to 1-hr control serum, but not 19-hr control 
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serum (Figure 4.2). No significant differences in IL-1β, TNFα, IL-10, MMP-3, MMP-13 
or TIMP-1, -2, -3, and -4 were present when comparing ACS to serum controls (Figures 
4.1 and 4.2). Within serum, the only MMP:TIMP ratios that demonstrated a significant 
increase in ACS compared to control were MMP-1 to TIMP-1, -2, -3, -4 and MMP-9 to 
TIMP-1, -2, -4 (Figure 4.3). Marked variability was present between horses in IL-1ra 
concentration in ACS (42% CV). Thirteen of the 14 additional analytes measured in ACS 
had a CV >15%, exceeding the inter-assay CV of 12% (Table 4.3).  
 
 Concentration of IL-1ra decreased by approximately 10% when comparing 
thawed ACS at day 7 or 14 to fresh ACS at day 0; however, no significant change in IL-
1ra or other analytes could be identified as a result of freeze/thaw (Figures 4.1 and 4.2).  
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Biomarker	   Mean Concentration (with 
range) of Biomarkers in ACS 
[pg/ml] 
Standard 
Deviation	  
Coefficient 
of 
Variation	  
Number 
of Values 
Below 
LLOQ	  IL-­‐1ra	   6585	  (3600	  –	  13299)	   2750	   41.76%	   0/11	  IL-­‐1β	   0.3860	  (0.043	  –	  0.91)	   0.2926	   75.81%	   2/11	  TNFα	   2.481	  (0.191	  –	  12.24)	   3.502	   141.15%	   4/11	  IL-­‐4	   4.513	  (3.56	  –	  12.92)	   2.809	   62.24%	   9/11	  IL-­‐6	   0.2387	  (0.052	  –	  0.97)	   0.3366	   141.01%	   8/11	  IL-­‐8	   261.2	  (18.4	  –	  686.23)	   292.2	   111.89%	   0/11	  IL-­‐10	   0.1198	  (0.056	  –	  0.44)	   0.1238	   103.32%	   8/11	  MMP-­‐1	   1441	  (817.57	  –	  2187.52)	   466.2	   32.36%	   0/11	  MMP-­‐3	   76.91	  (33.71	  –	  194.04)	   50.19	   65.25%	   0/11	  MMP-­‐9	   62720	  (32545	  –	  103756)	   21658	   34.53%	   0/11	  MMP-­‐13	   47.16	   0.0	   0.00%	   11/11	  TIMP-­‐1	   378.9	  (248.71	  –	  465.57)	   60.85	   16.06%	   0/11	  TIMP-­‐2	   166343	  (92980	  –	  577762)	   138033	   82.98%	   0/11	  TIMP-­‐3	   46858	  (17666	  –	  93908)	   25716	   54.88%	   0/11	  TIMP-­‐4	   73.69	  (51.39	  –	  101.97)	   16.00	   21.72%	   0/11	  
 
TABLE 4.3 - Overview of cytokine, matrix metalloproteinase, and tissue inhibitors of 
matrix metalloproteinase profile within autologous conditioned serum. Number of values 
below LLOQ (LLOQ = lower limit of quantification) outlines number of analytes that 
measured below lowest standard curve point. For these values, half of the lower limit of 
detection [lowest value statistically different from a blank at 99% confidence] for each 
individual analyte was used as the concentration. 
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FIGURE 4.1 - Median serum concentrations (with interquartile range) of cytokines IL-
1ra, IL-1β, IL-1ra to IL-1β ratio, TNFα, IL-4, IL-6, IL-8, IL-10. Groups included 1-hour 
unconditioned, unincubated control serum (1HR), 19-hour unconditioned, incubated 
control serum (19HR), fresh autologous conditioned serum (ACS), day 7 freeze-thaw 
ACS (7FT) and day 14 freeze-thaw ACS (14FT). Parametric analyses were performed on 
IL-1ra and IL-8, whereas non-parametric analyses were performed on IL-1β, IL-1ra:IL-
1β ratio, IL-4, IL-6, IL-10, and TNFα. Different letters indicate significant differences 
between groups (P<0.05). 
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FIGURE 4.2 – Median serum concentrations (with interquartile range) of matrix 
metalloproteinases (MMP) -1, -3, -9, and -13, and tissue inhibitors of matrix 
metalloproteinases (TIMP) -1, -2, -3, and -4. See Figure 4.2 legend for group definitions. 
Parametric analyses were performed on MMP-1, MMP-9, TIMP-1, TIMP-2, TIMP-3, 
and TIMP-4, whereas non-parametric analyses were performed on MMP-3 and MMP-13. 
Different letters indicate significant differences between groups (P<0.05). Note: all 
values for MMP-13 represent 50% of the lower limit of detection. 
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FIGURE 4.3 - Median serum MMP to TIMP ratios in 1-hour unconditioned, unincubated 
control serum (1 HR), 19-hour unconditioned, incubated control serum (19 HR), and 
autologous conditioned serum (ACS) groups. Asterisks denote significant difference 
between 1 HR, 19 HR or ACS groups. Significance was set at P<0.05. Parametric ratios 
include MMP1:TIMP1, MMP1:TIMP3, MMP1:TIMP4, MMP3:TIMP3, MMP9:TIMP1, 
MMP9:TIMP3, MMP9:TIMP4, MMP13:TIMP3, and MMP13:TIMP4. Non-parametric 
ratios include MMP1:TIMP2, MMP3:TIMP1, MMP3:TIMP2, MMP3:TIMP4, 
MMP9:TIMP2, MMP13:TIMP1, and MMP13:TIMP2.  
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PART C -  SYNOVIAL FLUID 
 
 Synovial fluid collected 7 days after intra-articular ACS injection only had 1% of 
the IL-1ra concentration that was present within the injected ACS product. This finding 
was consistent after all 3 injections (Figure 4.4). There was no significant change in 
concentrations of any cytokine, MMP, TIMP or MMP:TIMP ratio when comparing post-
ACS treatment synovial fluid to baseline.  
 
 When evaluating synovial fluid for changes in IL-1ra concentrations based on 
percent change from baseline, 5/11 horses displayed a consistent decrease in 
concentration at day 7, 14, 21, whereas 2/11 horses displayed a consistent increase in 
concentration. The remaining 4 horses showed a mixed response (both decrease/increase 
noted). For other analyte changes, trends were grouped relative to whether IL-1ra 
increased, decreased or were mixed in response. For these trends, it is imperative to note 
that no statistics could be performed due to the small sizes present per group. In horses 
that demonstrated decreased IL-1ra concentrations over time, a concurrent decrease in IL-
8, IL-10 and TIMP-3 also simultaneously occurred. In horses where IL-1ra increased 
over time, concentrations of IL-1β, TNFα (day 7, 14 only), and MMP-9 increased (Figure 
4.5). Overall, higher concentrations of MMP -1, -9, and -13 and TIMP -1, -2, -3, and -4 
were measured when IL-1ra consistently increased compared to the IL-1ra decrease 
group (Table 4.4). No trends in other analytes were discernable when IL-1ra response 
was mixed over time. 
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FIGURE 4.4 – Median concentrations (with interquartile range) of IL-1ra from 
autologous conditioned serum (ACS-black bars) administered intra-articularly (IA) 
compared to subsequent synovial fluid (SF-grey bars) samples collected after 7-day 
intervals. [1HR Serum=Serum IL-1ra concentration prior to conditioning (control); D0 
SF=Synovial fluid IL-1ra concentration in OA joints at baseline; D0 ACS=ACS IL-1ra 
concentration on day 0; D7 SF=SF IL-1ra concentration 7 days after IA administration of 
D0 ACS; D7 ACS=ACS IL-1ra concentration after freeze/thaw on Day 7; D14 SF=SF 
IL-1ra concentration 7 days after IA administration of D7 ACS; D14 ACS=ACS IL-1ra 
concentration after freeze/thaw on Day 14; D21 SF=SF IL-1ra concentration 7 days after 
IA administration of D14 ACS]. 
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FIGURE 4.5 – Median concentrations (with interquartile range) of analytes in synovial 
fluid, following further grouping of horses based on whether IL-1ra consistently 
increased or decreased compared to baseline. Note: These changes were not analyzed 
statistically due to the small numbers per group.  (A) Left Column:  In horses (n = 5) 
where concentration of IL-1ra consistently decreased on day 7, 14, 21 (compared to day 
0), there were also concurrent decreases in IL-8, IL-10, and TIMP-3. (B) Right Column:  
In horses (n = 2) where concentration of IL-1ra consistently increased on day 7, 14, 21 
(compared to day 0), there were also concurrent increases in IL-1β, TNFα (day 7, 14 
only), and MMP-9. 
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ANALYTE IL-1ra Increase Group 
(pg/ml) 
IL-1ra Decrease Group 
(pg/ml) 
MMP-1 261.1 127.8 
MMP-9 1215 139.6 
MMP-13 193.3 89.27 
TIMP-1 158.8 134.3 
TIMP-2 365121 122824 
TIMP-3 7860 5050 
TIMP-4 71.62 21.81 
 
TABLE 4.4 - Higher median concentrations (pg/ml) of MMP -1, -9, and -13 and TIMP -
1, -2, -3, and -4 were measured for horses where IL-1ra concentration consistently 
increased (n=2) compared to horses where the IL-1ra concentration consistently 
decreased (n=5), when averaged across study duration.   
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PART D -  LAMENESS 
 
 Two horses switched lameness to the contralateral forelimb between inclusion 
exam and day 0. Assessment of horses for inclusion occurred on average 45 days prior to 
the start of the study (range 7 to 97 days). Because we were interested in the response of 
the treated limb only, these 2 horses were removed from further lameness analyses. 
Median lameness grade for the remaining 9 horses before and after ACS administration 
was 1/5 for all time points (days 0, 7, 14, and 21). The average measure intraclass 
correlation coefficient for agreement of observers’ lameness grades was 0.946 (≥ 0.80 is 
acceptable). There was no significant difference noted within the study population when 
evaluating flexion test response following ACS therapy. 
 
PART E - CORRELATIONS 
 
 IL-1ra was positively correlated with IL-1β and TNFα in ACS, and TNFα, IL-8, 
MMP -9 and -13, as well as TIMP -1, -2, -3, and -4 in synovial fluid (Table 4.5). No 
significant correlations were present between arthrocentesis attempts, blood 
contamination, and joint effusion. Number of arthrocentesis attempts required was 
positively correlated to MMP-13 (p=0.04, r=0.323) and TIMP-1 (p=0.007, r=0.415) 
synovial fluid concentrations. The presence of blood contamination in synovial fluid was 
positively correlated to IL-8 (p=0.003, r=0.447), MMP-1 (p=0.0008, r=0.491), and 
MMP-9 (p=0.024, r=0.345) concentrations. When radiographic grade of DIP joint OA 
and navicular disease were summed with joint effusion and lameness and then compared 
to IL-1ra concentration in ACS, a negative correlation was present (P=0.036, R= -0.690).  
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AUTOLOGOUS CONDITIONED SERUM 
 P R 
IL-1ra to IL-1 β 0.009 0.758 
IL-1ra to TNFα 0.032 0.637 
SYNOVIAL FLUID 
 P R 
IL-1ra to TNFα 0.004 0.435 
IL-1ra to IL-8 0.005 0.417 
IL-1ra to MMP-9 0.04 0.432 
IL-1ra to MMP-13 0.027 0.345 
IL-1ra to TIMP-1 <0.001 0.680 
IL-1ra to TIMP-2 <0.001 0.541 
IL-1ra to TIMP-3 0.01 0.398 
IL-1ra to TIMP 4 0.001 0.514 
 
TABLE 4.5 – Significant (P<0.05) correlations between IL-1ra and various biomarkers in 
ACS and synovial fluid from all sampling time points, determined using Spearman rank 
correlation. 
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CHAPTER 5: 
DISCUSSION 
 
 
PART A -  SERUM 
 
 IL-1ra has been advocated as one of the main contributors to the anti-
inflammatory effect of ACS. Our study confirms previous reports that IL-1ra 
concentrations are substantially elevated in equine-derived ACS compared to 1-hr control 
serum [Frisbie 2007, Hraha 2011, Fjordbakk 2015]. Our results also show that IL-1ra 
concentrations in ACS were not significantly different compared to 19-hr control serum, 
which is in contrast to those reported by Hraha et al. where the IRAP IIb kit demonstrated 
higher IL-1ra concentration in ACS compared to both unincubated and incubated control 
serum [Hraha 2011]. The reason for this disparity is not clear, but could be related to our 
shorter incubation time (19 vs. 24 hours) since it has been shown that IL-1ra 
concentration continues to steadily increase up to 24 hours [Meijer 2003]. In our study, 
aiming for 18-20 hours of incubation remained within manufacturer recommendations 
(16-24 hours)b and was more convenient when used with client owned-horses. Our results 
do, however, concur with other human and veterinary studies that used other commercial 
ACS kits [Hraha 2011, Fjordbakk 2015, Magalon 2014]. This lack of difference in IL-1ra 
concentrations between ACS and incubated serum has led some to propose that 
conditioning of serum with glass beads may be unnecessary [Hraha 2011, Fjordbakk 
2015, Magalon 2014]. This conclusion was based on the fact that control serum incubated 
in plastic (non-glass) syringes [Fjordbakk 2015, Magalon 2014] or glass blood-collection 
tubes [Hraha 2011] demonstrated elevated IL-1ra concentrations that were no different 
than ACS. Nonetheless, it is important to consider that there are other components in 
ACS besides IL-1ra that may contribute to its action in vivo.  
 
 Our study identified lower concentrations of IL-4, -6, and -8 compared to 19-hr 
control. Physiologically, these cytokines have an anti-inflammatory (IL-4), immuno-
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modulatory (IL-6), and pro-inflammatory (IL-8) effect within the joint [Platt 1996] 
making it difficult to interpret the clinical relevance of their suppression. Similar 
differences between ACS and incubated controls (24-hr) have been found in previous 
equine studies, where IGF-1 concentrations in ACS were elevated compared to incubated 
controls [Hraha 2011]. Combined, these results suggest that ACS may be different in 
composition compared to incubated control serum (19- or 24-hr), such that one cannot 
assume that incubating serum without glass beads will result in the same product. To our 
knowledge, this has not been previously reported in equine-derived ACS.  
 
 ACS is considered anti-inflammatory and concurrent increases in catabolic 
cytokines or degradative enzymes would be undesirable. We noted no change in IL-1β 
and TNFα concentrations, which is different than previous equine-derived ACS studies 
[Hraha 2011, Fjordbakk 2015]. Those studies both demonstrated increased IL-1β in ACS 
compared to unincubated controls, whereas TNFα was increased in ACS in only one 
study [Hraha 2011]. We could, however, demonstrate a significant positive correlation 
between IL-1ra and both IL-1β and TNFα in ACS, suggesting that there is at least a 
modulatory response between all 3 cytokines. Our results also illustrated a significant 
elevation in MMP-1 and MMP-9 activity in ACS when compared to 1-hr control serum. 
This may be important because the increase in MMPs was disproportionate to the TIMPs 
as demonstrated by their ratios. To our knowledge, no previous studies have investigated 
MMP or TIMP profile in equine-derived ACS. MMPs are actively involved in catabolism 
of articular cartilage; MMP-1 functions to denature type II collagen, whereas MMP-9 
degrades gelatin and unwind denatured collagen [McIlwraith 1996]. Although the 
increase in MMPs within ACS is clearly undesirable, a concurrent increase in MMP 
concentration or MMP:TIMP ratios was not evident in synovial fluid 7 days after any of 
the intra-articular injections of ACS. This might be because the TIMPs in synovial fluid 
positively correlated to IL-1ra concentration, leading to a protective effect even though 
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TIMP concentrations were not different in synovial fluid. Further research is required to 
better understand why MMPs increase in ACS. 
 
 In equine practice, it is common for ACS aliquots to be frozen after processing 
and stored for subsequent treatments at weekly or bi-weekly intervals. As such, ACS 
undergoes an additional freeze-thaw cycle and passage through a filter. To our 
knowledge, the effect of this has not been previously examined in equine ACS. 
Concentrations did decrease by approximately 10%, but there was no significant loss of 
the original ACS composition following one freeze-thaw cycle. We did not investigate 
prolonged storage, so it is unknown whether results would be the same for storage >2 
weeks. 
 
 Similar to other equine ACS investigations, concentration of IL-1ra in our study 
showed wide variability between individual horses [Frisbie 2007, Hraha 2011, Fjordbakk 
2015]. Variability was not isolated to IL-1ra alone, as most other cytokine, MMP, and 
TIMP analytes had high CVs. Therefore, each dose of ACS must be considered unique. 
The effect of this variability on clinical response is unclear. 
 
 In osteoarthritis, IL-1 receptors within cartilage and synovium increase, leading to 
further potentiation of IL-1 induced inflammation [Fernandes 2002]. In addition, IL-1β 
itself is potent, such that small increases in IL-1β binding result in marked inflammation. 
As such, a disproportionally high amount of IL-1ra is required to antagonize IL-1β-
induced inflammation [Fernandes 2002]. The ratio of IL-1ra to IL-1β has been postulated 
as a means of estimating therapeutic efficacy of an ACS product [Meijer 2003], with 10:1 
(IL-1ra:IL-1β) being the minimum needed [Granowitz 1991]. When the overall clinical 
score of disease increased in our study, IL-1ra concentration in ACS decreased, meaning 
horses with more disease ultimately produced less IL-1ra in ACS. Nonetheless, our IL-
1ra:IL-1β ratios were much greater than 10:1, so IL-1ra concentrations achieved within 
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the ACS product was presumably adequate to inhibit IL-1β binding regardless of disease 
status.  
 
PART B - SYNOVIAL FLUID 
 
 In our study, IL-1ra concentrations were high in ACS, and ACS was serially 
administered intra-articularly. As such, we expected that synovial fluid IL-1ra 
concentrations would increase over time as the number of available IL-1 receptors 
decreased due to increased IL-1ra binding. However, similar to another equine study 
[Frisbie 2007], serial intra-articular administration at 7-day intervals did not result in 
increased IL-1ra concentrations in synovial fluid through day 21. Combined, this seems 
to suggest that IL-1ra becomes summarily bound to IL-1 receptors, with less free IL-1ra 
in synovial fluid. It is possible that if we followed these horses out longer, we may have 
seen a change in synovial fluid concentrations since horses with experimental OA 
demonstrated increased IL-1ra in synovial fluid 35 days after the 4th serial dose of ACS 
(Frisbie 2007).  However, it is not clear why it took that long for concentrations to 
increase.  It is important to recall that IL-1ra concentrations were combined from both the 
OA and sham operated joints within the osteochondral fragment study (Frisbie 2007). 
The reason why concentrations were combined, rather than being assessed individually, 
remains unclear. However, combining the concentrations may have misled the 
interpretation of change within IL-1ra. 
 
 It may be more likely that some IL-1ra will bind to IL-1 receptors in the joint, 
while most is either degraded or transported out of the joint within 7 days following ACS 
injection. One human osteoarthritis study concluded that ACS has minimal influence 
within joints due to rapid intra-articular clearance of IL-1ra [Rutgers 2010]; they saw no 
change in synovial fluid IL-1ra concentration when measured at 3-day intervals following 
6 ACS injections into human knees. The authors theorized that IL-1ra is not the central 
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protein responsible for the reported efficacy of ACS therapy, as is commonly assumed 
[Rutgers 2010]. Nonetheless, when combined with our study, it is clear that further 
research into the disposition of IL-1ra following intra-articular injection is needed to 
determine its effect in the joint. Additionally, due to the minimal change in IL-1ra 
concentration in synovial fluid, it was impossible to determine any influence on the 
necessity of serial dosing. 
 
 For many of the remaining analytes, concentrations in ACS were not different 
compared to 1-hr serum and no change would be expected following ACS therapy. For 
MMP-1 and MMP-9 (also significantly increased in ACS versus 1-hr serum), the lack of 
change in synovial fluid could have similarly been a direct result of rapid intra-articular 
clearance or protein degradation within the joint. Although not significant, IL-1β, TNFα, 
and MMP-9 illustrated a trend of concurrently increasing along with IL-1ra in synovial 
fluid. As previously mentioned, these three analytes were also significantly correlated in 
serum. Together, the modulatory relationship between IL-1ra, IL-1β, and TNFα may 
reflect response of the joint to increased IL-1ra. In other words, as IL-1ra increases due to 
ACS therapy, a natural increase in catabolic proteins occurs as well to maintain joint 
homeostasis. In the five horses that had consistently decreased IL-1ra, a trend of 
concurrently decreased IL-8, IL-10, and TIMP-3 was also noted. The mixed catabolic 
(IL-8) and anti-catabolic (IL-10 and TIMP-3) and low sample size (n=5) makes the 
interpretation of these trends difficult. 
 
 Of note, several biomarkers measured in this study were below the lower limit of 
detection, namely IL-1β, TNF-α, IL-4, IL-6, IL-10 and MMP-13 (Table 3.6). Another 
study using similar multiplex assay methodology compared normal vs. OA synovial fluid 
in humans, and found a high prevalence of samples below the lower limit of detection 
when evaluating IL-1β, IL-6 and IL-10 (Beekhuizen 2013). In other studies, (one 
comparing healthy vs. OA cartilage and another comparing normal vs. mild to moderate 
 
 
 68 
 
OA) there was no significant change in IL-1ra, IL-1β, IL-4, IL-6, IL-8 and IL-10 
concentrations identified between groups (Heard 2013, Tsuchida 2014). These similar 
results within various multiplex studies may suggest that the aforementioned biomarkers 
are not highly increased in osteoarthritis, in both humans and horses. 
 
 
PART C -  LAMENESS  
 
 Lameness improvement following ACS therapy was not evident in our study. 
Comparatively, when treating the carpal joint, significant improvement in lameness was 
reported 35 days after the last of 4 ACS doses [Frisbie 2007]. However, closer 
examination of that study reveals that the improvement in lameness was less than one full 
grade (based on American Association of Equine Practitioner scale) in magnitude. 
Potentially, examining more horses, providing more than 3 ACS doses, or monitoring for 
change in lameness beyond day 21 may have shown improved lameness scores in our 
study. Although three separate investigators graded gait videos blindly, video evaluation 
of lameness can be limited and not provide a complete representation of a horse’s 
movement. Additionally, visual lameness evaluation is inherently subjective. The 
addition of force-plate or kinematic gait analysis technology could better clarify the 
clinical effect of ACS therapy on lameness symptoms. 	  
  
 
PART D -  STUDY LIMITATIONS 
 
 There are important limitations to our study. First, an inherent variability exists 
when using naturally occurring cases of OA, which may negatively affect the power of 
the study. However, naturally occurring osteoarthritic cases provide the most accurate in 
vivo representation of clinical practice. Therefore, each joint served as its own control by 
 
 
 69 
 
comparing synovial fluid concentrations before and after ACS therapy to minimize this 
variability. Inclusion criteria for study horses with DIP osteoarthritis required exclusion 
of advanced navicular disease. Performing magnetic resonance imaging prior to study 
inclusion would provide better information compared to radiographs, however this was 
not financially feasible for this study.  
 
 Another limitation, especially when using client-owned horses, is the potential 
inability to recruit adequate numbers of osteoarthritic cases for study inclusion. In this 
study, 11 horses were enrolled and treated within the confines of the study timeframe. 
Based on power calculations, recruitment of 12 horses was proposed to achieve 80% 
power at an alpha of P<0.05. As such, the slightly lower sample size present may have 
contributed to overall lower power. 
 
 Other variables, such as arthrocentesis attempts and blood contamination, were 
found to correlate with certain analytes in synovial fluid. However, since no changes in 
the aforementioned biomarkers were seen over time in synovial fluid, the clinical impact 
of these correlations are unknown. Interestingly, blood contamination correlated with 
both IL-8 and MMP-9 concentrations. Both of these analytes are related to neutrophils, 
which may imply that a relevant correlation existed. Inclusion of a saline-injected 
osteoarthritic control group could provide better clarity regarding any influence of 
needle-induced inflammation.  
 
 The equine IL-1ra ELISA has been used successfully in previous investigations 
[Hraha 2011, Fjordbakk 2015]. However, this investigation is one of the first equine 
studies to use a human-based multiplex assay to quantitate multiple analytes. Human 
multiplex technology has been partially validated by the authors prior to onset of 
investigation (unpublished data). Human bead-based kits were utilized over rat or mice 
due to the high homology between amino acid sequences present between horses and 
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humans (Table 3.5). Potentially, using equine specific cytokine ELISAs or zymographic 
techniques for MMPs and TIMPs could yield more accurate results.  
 
PART E -  CONCLUSION 
 
In conclusion, although commercially available ACS kits appear to increase the 
concentration of IL-1ra in serum from horses, the lack of IL-1ra concentration change 
within synovial fluid is concerning. Quantifying the retention time of ACS-derived IL-1ra 
within the joint is an important question that remains. Although gait evaluation was a 
secondary focus of this study, the lack of improvement warrants future research regarding 
the ability of ACS to provide lameness improvement in naturally occurring cases of OA. 
Lastly, multiplex assay using human cytokine, MMP and TIMP kits are effective for 
measurement of equine biomarker concentrations. 
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CHAPTER 6: 
FUTURE DIRECTIONS 
 
 
 This investigation provides further clarity on the biomarker composition of 
equine-derived ACS, however not all potentially relevant biomarkers were assessed. 
Unfortunately, certain analytes of interest provided poor protein homology between 
human and equine amino acid sequences, had poor validation when using human-based 
kits and Luminex® xMAP® technology during preliminary studies, or were not 
financially feasible to include due to budget restrictions. Various other cytokines (IL-2, 
IL-5), growth factors [platelet-derived growth factor (PDGF), vascular endothelial 
growth factor (VEGF), insulin-like growth factor-1 (IGF-1), transforming growth factor 
beta (TGF-β)], or matrix metalloproteinases (MMP-2) could change in both ACS and 
subsequent synovial fluid following ACS therapy. In fact, others have documented 
change in biomarkers unmeasured in our study, such as TGF-β (Rutgers 2010, Hraha 
2011) and IGF-1 (Hraha 2011).  
 
 To further characterize the role of individual biomarkers within ACS, and learn 
about their individual influence on joint inflammation, further in vitro studies could be 
performed utilizing harvested chondrocyte samples that are exposed to IL-1β. Potentially, 
cartilage samples could be individually exposed to biomarkers, with subsequent 
measurements on cartilage metabolism. This study design has been previously utilized by 
Carlson et. al., however the study was directed towards exposure to ACS as a whole 
rather than individual biomarkers (Carlson 2013). Secondary to in vitro data, translation 
to an in vivo study using naturally occurring osteoarthritis could be attempted using 
recombinant versions of those proteins found to be relevant. 
 
 Horses enrolled in this study had low grades of radiographic OA (9 out of 11 
horses as either grade 0 or 1) and low grades of lameness (median grade 1 out of 5).  As 
 
 
 72 
 
such, the study population was characterized as mild. Potentially, enrollment of horses 
with more severe OA may result in ACS imparting a more noticeable clinical effect. That 
said, in this study a negative correlation was identified between IL-1ra concentrations in 
synovial fluid and worsening OA (identified by summation of various clinical 
parameters). Alternatively, creating two or more groups of horses with experimental OA 
(ie, osteochondral fragments) that are of varying severity may allow for interpretation of 
whether ACS is best suited for early/mild or advanced/severe OA. 
 
 This study also only provides insight on horses affected with naturally occurring 
osteoarthritis in the distal interphalangeal (DIP) joint. However, it remains unknown 
whether ACS acts similarly when utilized in other joints. Potentially, further in vivo 
research evaluating both biomarker change and clinical improvement when administering 
ACS into other joints of the horse could provide better indications for which joints ACS 
is best suited.  
 
 Potentially examining horses and synovial fluid samples beyond 21 days could 
identify different changes within various biomarker concentrations that were unidentified 
in our current study. Because Frisbie et. al. reported improvement in lameness scores 
following 4 serial ACS injections, performing a study using naturally occurring OA cases 
and >4 serial injections may provide further insight on ACS efficacy (Frisbie 2007).  
 
 We did not observe changes in biomarker concentrations within synovial fluid 
when samples were attained at 7 days intervals post-ACS administration. Potentially, 
decreasing the sampling interval such that samples are attained every 12 to 48 hours 
could provide further detail on the duration of exogenous IL-1ra (or other biomarkers) 
within the joint environment. However, with additional arthrocentesis attempts, more 
iatrogenic inflammation can result which can make interpretation of biomarker 
concentrations difficult (Brama 2004).  
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 This study was designed as a prospective clinical trial, wherein each treated joint 
was compared to baseline synovial fluid values collected at day 0. However, a stronger 
level of evidence-based medicine could be attained through developing a randomized, 
blinded, controlled clinical trial. With this study design, a true placebo-injected control 
group would exist. This would allow better separation of change in biomarker 
concentrations due to arthrocentesis or fluid volume change within the joint. 
Alternatively, enrolling more horses into the current study would help further strengthen 
the study. 
 
 Lameness is the ultimate clinical symptom that drives client concern. Although 
ACS may provide anti-inflammatory benefit to the joint, if lameness symptoms (which 
are driven by pain within the joint environment) persist following ACS therapy, then the 
effectiveness of ACS as a practical therapy should be questioned. Strengthening the 
assessment of clinical outcome using force-plate or kinematic motion analysis software 
would strengthen the acceptance/rejection of ACS as a successful therapeutic for 
management of lameness due to the limitations of subjective gait assessment. 
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CHAPTER 7: 
FOOTNOTES 
 
 
(a) Orthokine® Vet IRAP 10, Dechra Veterinary Products, Overland Park, Kansas, USA. 
(b) IRAPTM II System, Arthrex Vet Systems, Naples, Florida, USA. 
(c) R & D Systems, Minneapolis, Minnesota, USA. 
(d) 0.2µm Whatman Syringe Filter, GE Healthcare, Barrington, Illinois, USA 
(e) Centrifuge Model #5702, Eppendorf North America, Hauppauge, New York, USA. 
(f) Dormosedan® (10 mg/ml), Zoetis Animal Health, Florham Park, New Jersey, USA. 
(g) Lidocaine hydrochloride 2%®, Zoetis Animal Health, Florham Park, New Jersey, 
USA. 
(h) Luminex® Liquichip Workstation IS200, BioRad Labratories, Hercules, California, 
USA. 
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